[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 144
1. Canis M, Farina M, Jardon K, Rabischong B, Rivoire C, Nohuz E, Botchorishvili R, Pouly JL, Mage G: [Laparoscopy and gynecologic cancer in 2005]. J Gynecol Obstet Biol Reprod (Paris); 2006 Apr;35(2):117-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopy and gynecologic cancer in 2005].
  • All the surgical procedures, which may be required to treat a gynecologic cancer, can be performed endoscopically.
  • Animal studies suggested that the risk of tumor dissemination in non traumatized peritoneum is higher after a pneumoperitoneum than after a laparotomy.
  • Changing these parameters we may, in the future, be able to create a peritoneal environment adapted to oncologic patients in order to prevent or to decrease the risks of peritoneal dissemination and/or of postoperative tumor growth.
  • In contrast restaging of an early ovarian cancer initially managed as a benign mass, is a good indication of the laparoscopic approach.
  • Teaching and diffusion of endoscopic oncological techniques are among the major challenges of gynecologic surgery within the next few years.
  • [MeSH-major] Genital Neoplasms, Female / surgery. Laparoscopy
  • [MeSH-minor] Animals. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Female. Humans. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Peritoneal Neoplasms / epidemiology. Peritoneal Neoplasms / etiology. Pneumoperitoneum, Artificial / adverse effects. Risk Factors. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575358.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 190
  •  go-up   go-down


2. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr, Lokshin A: Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol; 2010 Jun;117(3):440-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.
  • Our subject group consisted of women diagnosed with benign masses and early- and late-stage ovarian cancer.
  • RESULTS: More than half of the biomarkers tested were found to differ significantly between benign and malignant cases.
  • As individual markers, HE4 and CA-125 provided the greatest level of discrimination between benign and malignant cases, and the combination of these two biomarkers provided a higher level of discriminatory power than either marker considered alone.
  • Multivariate statistical analysis identified several multimarker panels that could discriminate early-stage, late-stage, and combined ovarian cancers from benign cases with similar or slightly improved SN/SP levels to the CA-125/HE4 combination; however, these larger panels could not outperform the 2-biomarker panel in an independent validation set.
  • CONCLUSIONS: Our findings serve to advance the development of blood-based screening methods for the discrimination of benign and malignant ovarian masses by confirming and expanding upon the superior utility of the CA-125/HE4 combination.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Int J Cancer Suppl. 1988;3:61-7 [3209301.001]
  • [Cites] Cancer. 1987 Aug 1;60(3):353-61 [3594371.001]
  • [Cites] Gynecol Oncol. 1992 Nov;47(2):203-9 [1468698.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):707-13 [7687515.001]
  • [Cites] Gynecol Oncol. 1995 Mar;56(3):402-5 [7535720.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):111-6 [7557595.001]
  • [Cites] Cancer. 1997 May 1;79(9):1647-55 [9128978.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 1997 Mar-Apr;59(2):106-14 [9166881.001]
  • [Cites] Am Fam Physician. 1998 May 15;57(10):2471-6, 2479-80 [9614415.001]
  • [Cites] Oncology. 2004;67(3-4):225-30 [15557783.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7 [15824174.001]
  • [Cites] Hum Cell. 2004 Dec;17(4):203-9 [16035505.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 1;98(3):172-80 [16449677.001]
  • [Cites] Mol Cancer Ther. 2006 Feb;5(2):382-90 [16505113.001]
  • [Cites] Clin Obstet Gynecol. 2006 Sep;49(3):448-58 [16885652.001]
  • [Cites] Cancer. 2007 May 1;109(9):1887-96 [17373668.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):297-308 [17569106.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):402-8 [18061248.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1065-72 [18258665.001]
  • [Cites] Biochim Biophys Acta. 2008 Apr;1785(2):232-65 [18291115.001]
  • [Cites] Obstet Gynecol Clin North Am. 2008 Jun;35(2):271-84, ix [18486841.001]
  • [Cites] Br J Cancer. 2008 Oct 7;99(7):1103-13 [18766180.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2872-81 [18843033.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):40-6 [18851871.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):47-54 [19007974.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2647-56 [19351767.001]
  • [Cites] Am J Obstet Gynecol. 2009 Jun;200(6):639.e1-5 [19285648.001]
  • [Cites] J Clin Oncol. 2010 May 1;28(13):2159-66 [20368574.001]
  • [Cites] Am J Obstet Gynecol. 1988 Aug;159(2):341-6 [2457318.001]
  • [Cites] Eur J Gynaecol Oncol. 2000;21(2):141-5 [10843472.001]
  • [Cites] Int J Gynecol Cancer. 2001 Jul-Aug;11(4):277-82 [11520365.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1248-59 [11870167.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):103-13 [12582019.001]
  • [Cites] Obstet Gynecol. 2003 Sep;102(3):499-505 [12962932.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3):662-6 [13678742.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Nurs Clin North Am. 1992 Dec;27(4):835-45 [1448359.001]
  • (PMID = 20334903.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098642-03; United States / NCI NIH HHS / CA / R01 CA098642; United States / NCI NIH HHS / CA / R01 CA108990; United States / NCI NIH HHS / CA / R01 CA098642-02; United States / NCI NIH HHS / CA / R01 CA098642-01A1; United States / NCI NIH HHS / CA / R01 CA108990-02; United States / NCI NIH HHS / CA / R01 CA108990-01; United States / NCI NIH HHS / CA / R01 CA108990-05; United States / NCI NIH HHS / CA / R01 CA108990-04; United States / NCI NIH HHS / CA / R01 CA108990-05S1; United States / NCI NIH HHS / CA / R01 CA098642-04; United States / NCI NIH HHS / CA / R01 CA108990-01A1; United States / NCI NIH HHS / CA / R01 CA108990-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / beta-Defensins
  • [Other-IDs] NLM/ NIHMS192224; NLM/ PMC2873171
  •  go-up   go-down


3. Liao SY, Rodgers WH, Kauderer J, Bonfiglio TA, Walker JL, Darcy KM, Carter R, Hatae M, Levine L, Spirtos NM, Stanbridge EJ: Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States. Int J Cancer; 2009 Nov 15;125(10):2434-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States.
  • In the cervix, carbonic anhydrase IX (CA-IX) is expressed in cervical neoplasia, but rarely in the benign cervix.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Jul;30(7):816-25 [10414501.001]
  • [Cites] Am J Obstet Gynecol. 1998 Aug;179(2):382-90 [9731842.001]
  • [Cites] Diagn Cytopathol. 2006 Mar;34(3):235-9 [16470857.001]
  • [Cites] Am J Obstet Gynecol. 2005 Aug;193(2):559-65; discussion 565-7 [16098895.001]
  • [Cites] Vaccine. 2008 Aug 19;26 Suppl 10:K1-16 [18847553.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1007-13 [16803477.001]
  • [Cites] J Clin Microbiol. 2006 Nov;44(11):3915-7 [16971652.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1108-21 [10699902.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):97-105 [10926787.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1055-62 [11021808.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):905-19 [11238039.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3660-8 [11504747.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6394-9 [11522632.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):222-7 [11668502.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):96-102 [11789738.001]
  • [Cites] Cancer. 2002 Feb 25;96(1):1-4 [11836696.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2114-9 [11966386.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2120-9 [11966387.001]
  • [Cites] Diagn Cytopathol. 2003 Nov;29(5):271-9 [14595795.001]
  • [Cites] Am J Clin Pathol. 2004 Jan;121(1):87-92 [14750245.001]
  • [Cites] Gynecol Oncol. 1989 Oct;35(1):1-7 [2792895.001]
  • [Cites] Acta Cytol. 1993 Mar-Apr;37(2):115-24 [8465628.001]
  • [Cites] Int J Cancer. 1993 May 8;54(2):268-74 [8486430.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):598-609 [8080042.001]
  • [Cites] Oncogene. 1994 Oct;9(10):2877-88 [8084592.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):549-57 [8827360.001]
  • [Cites] Gynecol Oncol. 1996 Oct;63(1):14-8 [8898161.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2827-31 [9230182.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1248-54 [18483347.001]
  • (PMID = 19670419.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA037517-25; United States / NCI NIH HHS / CA / CA027469-29; United States / NCI NIH HHS / CA / CA 11479; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA037517; None / None / / U10 CA037517-25; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / U10 CA027469-29
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Viral; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ NIHMS137629; NLM/ PMC2779726
  •  go-up   go-down


Advertisement
4. Gagnon A, Kim JH, Schorge JO, Ye B, Liu B, Hasselblatt K, Welch WR, Bandera CA, Mok SC: Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res; 2008 Feb 1;14(3):764-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.
  • Therefore, the possibility of using autoantibodies directed against tumor-associated antigens as putative cancer markers is being more examined.
  • To do so, we developed an innovative technique called two-dimensional differential gel electrophoresis analysis of immunoprecipitated tumor antigens.
  • Further real-time reverse transcription-PCR and immunohistochemical studies confirmed that the S100A7 mRNA and protein were highly expressed in ovarian tumors but absent in normal and benign tissues.
  • Moreover, a preliminary study involving 138 patients confirmed that the plasma levels of anti-S100A7 antibodies are significantly elevated in early- and late-stage ovarian cancer patients compared with healthy controls and with patients with benign gynecologic diseases.
  • CONCLUSIONS: This shows that our approach is a valuable tool to successfully identify autoantibodies and tumor-associated antigens in cancer patients and that future research assessing their putative clinical usefulness would be worthwhile.
  • [MeSH-major] Antigens, Neoplasm / blood. Autoantibodies / blood. Ovarian Neoplasms / immunology
  • [MeSH-minor] Cell Line, Tumor. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Immunoglobulin G / blood. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18245537.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA105009; United States / NCI NIH HHS / CA / R33CA103595; United States / NCI NIH HHS / CA / UO1CA86381
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Immunoglobulin G; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


5. Anderson NS, Bermudez Y, Badgwell D, Chen R, Nicosia SV, Bast RC Jr, Kruk PA: Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol Oncol; 2009 Jan;112(1):60-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Bcl-2 was assayed by ELISA in urine samples from two cohorts consisting of a total of 77 healthy women, 161 women with benign gynecologic disease and 150 women with ovarian cancer, 13 with early and 137 with late stage disease, respectively.
  • RESULTS: Urinary levels of Bcl-2 from healthy individuals or women with benign disease averaged 0.59 ng/ml+/-0.61 and 1.12 ng/ml+/-0.79, respectively.
  • Further, urinary levels of Bcl-2 were elevated in ovarian cancer patients regardless of tumor grade, stage, size, histologic subtype, creatinine levels or patient age, but appeared to complement CA125 measurements.
  • [MeSH-major] Biomarkers, Tumor / urine. Ovarian Neoplasms / urine. Proto-Oncogene Proteins c-bcl-2 / urine
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CA-125 Antigen / blood. Cohort Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. Risk Factors

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Detect Prev. 2002;26(2):149-57 [12102150.001]
  • [Cites] FASEB J. 2002 Sep;16(11):1453-5 [12205045.001]
  • [Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):720-7 [12445249.001]
  • [Cites] J Cell Sci. 2003 Nov 15;116(Pt 22):4493-9 [14576343.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2074-80 [12931228.001]
  • [Cites] Int J Gynecol Pathol. 2004 Apr;23(2):162-9 [15084845.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1185-91 [15247129.001]
  • [Cites] Hum Reprod. 1989 Jan;4(1):1-12 [2651469.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 3;85(21):1748-51 [8411259.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):485-95 [10688869.001]
  • [Cites] Int J Mol Med. 2000 May;5(5):547-51 [10762660.001]
  • [Cites] Exp Cell Res. 2000 Apr 10;256(1):12-8 [10739646.001]
  • [Cites] Exp Cell Res. 2000 Apr 10;256(1):19-26 [10739647.001]
  • [Cites] Exp Cell Res. 2000 Apr 10;256(1):58-66 [10739652.001]
  • [Cites] JAMA. 2001 Jan 17;285(3):324-8 [11176843.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2183-8 [11280784.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Curr Opin Genet Dev. 1996 Feb;6(1):45-9 [8791486.001]
  • [Cites] J Biol Chem. 1999 Apr 16;274(16):11245-52 [10196212.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):823-9 [10213218.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7457-65 [15569975.001]
  • [Cites] Cancer Detect Prev. 2005;29(3):256-9 [15899555.001]
  • [Cites] Gynecol Oncol. 2007 Sep;106(3):490-7 [17532030.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7296-304 [18094410.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • (PMID = 19007973.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / P50 CA083639
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2
  • [Other-IDs] NLM/ NIHMS232262; NLM/ PMC3729448
  •  go-up   go-down


6. Shih IeM, Chen L, Wang CC, Gu J, Davidson B, Cope L, Kurman RJ, Xuan J, Wang TL: Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. Am J Obstet Gynecol; 2010 Dec;203(6):584.e1-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The purpose of this study was to analyze DNA methylation profiles among different types of ovarian serous neoplasm, which is a task that has not been performed.
  • STUDY DESIGN: The Illumina beads array (Illumina Inc, San Diego, CA) was used to profile DNA methylation in enriched tumor cells that had been isolated from 75 benign and malignant serous tumor tissues and 6 tumor-associated stromal cell cultures.
  • Unsupervised analysis identified that serous cystadenoma, serous borderline tumor, and low-grade serous carcinomas tightly clustered together and were clearly different from high-grade serous carcinomas.
  • CONCLUSION: The findings support the view that low-grade and high-grade serous carcinomas are distinctly different with low-grade, but not high-grade, serous carcinomas that are related to serous borderline tumor and cystadenoma.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] Clin Cancer Res. 2010 Apr 1;16(7):1997-2008 [20233889.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • [Cites] J Biochem. 2003 Mar;133(3):303-8 [12761165.001]
  • [Cites] Nat Genet. 2003 Jul;34(3):337-43 [12819783.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):252-6 [14760118.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6476-81 [15374957.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6915-8 [15466181.001]
  • [Cites] Curr Opin Oncol. 2005 Jan;17(1):33-8 [15608510.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4963-8 [15930319.001]
  • [Cites] Oncogene. 2005 Jun 2;24(24):3875-85 [15735666.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1924-30 [16134181.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7273-9 [16243797.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):107-16 [16491070.001]
  • [Cites] Virchows Arch. 2006 Mar;448(3):331-6 [16315018.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):299-308 [16773633.001]
  • [Cites] Am J Surg Pathol. 2007 Jul;31(7):1007-12 [17592266.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] J Urol. 2008 Feb;179(2):743-7 [18082200.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):151-60 [18317228.001]
  • [Cites] Gynecol Oncol. 2008 Apr;109(1):129-39 [18234305.001]
  • [Cites] Int J Cancer. 2008 Aug 1;123(3):725-9 [18478570.001]
  • [Cites] Gynecol Oncol. 2008 Nov;111(2):320-9 [18757082.001]
  • [Cites] Am J Obstet Gynecol. 2009 Feb;200(2):177.e1-9 [19110234.001]
  • [Cites] Annu Rev Pathol. 2009;4:287-313 [18842102.001]
  • [Cites] Cancer Res. 2009 May 1;69(9):4036-42 [19383911.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8482-90 [19826047.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5874-80 [19901110.001]
  • [Cites] PLoS One. 2010;5(2):e9359 [20179752.001]
  • [Cites] Lab Invest. 2010 Mar;90(3):414-25 [20065949.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2246-52 [12114427.001]
  • (PMID = 20965493.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA103937; United States / NCI NIH HHS / CA / CA103937-07; United States / NCI NIH HHS / CA / R01 CA129080-04; United States / NCI NIH HHS / CA / CA129080; United States / NCI NIH HHS / CA / R01 CA129080; United States / NCI NIH HHS / CA / CA129080-04; United States / NCI NIH HHS / CA / R01 CA103937-07; United States / NCI NIH HHS / CA / R01 CA103937
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS230506; NLM/ PMC2993872
  •  go-up   go-down


7. Chalas E, Costantino JP, Wickerham DL, Wolmark N, Lewis GC, Bergman C, Runowicz CD: Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol; 2005 Apr;192(4):1230-7; discussion 1237-9
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.
  • OBJECTIVE: This study was undertaken to report on the benign gynecologic conditions occurring among women with an intact uterus at enrollment in the Breast Cancer Prevention Trial of the National Surgical Adjuvant Breast and Bowel Project.
  • STUDY DESIGN: The incidence rates of several benign gynecologic conditions were determined and risks were compared among women receiving tamoxifen and those receiving placebo, based on risk ratios (RRs) with 95% CIs.
  • RESULTS: Compared with women taking placebo, premenopausal women taking tamoxifen had a greater incidence of endometrial polyps (RR = 1.9, 95% CI = 1.55-2.41), leiomyomas (RR = 1.3, 95% CI = 1.14-1.55), endometriosis (RR = 1.9, 95% CI = 1.35-2.70), ovarian cysts (RR = 1.5, 95% CI = 1.20-1.78), and gynecologic surgical procedures, including hysterectomy (RR = 1.6, 95% CI = 1.29-1.88).
  • Postmenopausal women taking tamoxifen also had an increased incidence of endometrial polyps (RR = 2.4, 95% CI = 1.76-3.24), leiomyomas (RR = 1.4, 95% CI = 1.04-1.80), endometriosis (RR = 1.9, 95% CI = 1.29-5.58), and gynecologic surgical procedures, including hysterectomy (RR = 2.2, 95% CI = 1.60-3.13), compared with women taking placebo.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / therapy. Genital Diseases, Female / chemically induced. Genital Diseases, Female / pathology. Neoplasm Recurrence, Local / prevention & control. Tamoxifen / adverse effects
  • [MeSH-minor] Adult. Age Distribution. Aged. Chemotherapy, Adjuvant. Confidence Intervals. Dose-Response Relationship, Drug. Female. Humans. Incidence. Middle Aged. Neoplasm Staging. Probability. Reference Values. Risk Assessment

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Obstet Gynecol. 2006 Apr;194(4):1204-5; author reply 1205 [16580343.001]
  • (PMID = 15846210.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10-CA-37377; United States / NCI NIH HHS / CA / U10-CA-69974
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


8. Dominical VM, Cavellani CL, Rocha LP, Corrêa RR, Pereira Gde A, Teixeira Vde P: Chagas disease and gynecologic neoplasias. Ann Diagn Pathol; 2010 Oct;14(5):337-40
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chagas disease and gynecologic neoplasias.
  • The objective was to determine the occurrence of gynecologic neoplasia (GN) and demographic characteristics in patients with Chagas disease (CD).
  • The most common benign neoplasm was uterine leiomyoma, and malignant, carcinoma of the cervix.
  • [MeSH-minor] Brazil / epidemiology. Comorbidity. Female. Humans. Middle Aged


9. Turnbull L, Booth S: MR imaging of gynecologic diseases at 3T. Magn Reson Imaging Clin N Am; 2007 Aug;15(3):403-31, vii-viii
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging of gynecologic diseases at 3T.
  • MR imaging using anatomic, chemical, and functional information offers huge potential for the management of the gynecologic patient.
  • By differentiating benign from malignant disease with very high specificity, it can aid the selection of patients requiring further treatment and determine the level of urgency.
  • This article compares and contrasts MR imaging of gynecologic conditions at 1.5 and 3T and defines a role for high field imaging for these clinical conditions.
  • [MeSH-major] Genital Diseases, Female / diagnosis. Image Enhancement / methods. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Artifacts. Diagnosis, Differential. Female. Humans. Neoplasm Staging. Neoplasm, Residual. Ovarian Diseases / diagnosis. Ovarian Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17893060.001).
  • [ISSN] 1064-9689
  • [Journal-full-title] Magnetic resonance imaging clinics of North America
  • [ISO-abbreviation] Magn Reson Imaging Clin N Am
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


10. Field JB, Benoit MF, Dinh TA, Diaz-Arrastia C: Computer-enhanced robotic surgery in gynecologic oncology. Surg Endosc; 2007 Feb;21(2):244-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-enhanced robotic surgery in gynecologic oncology.
  • BACKGROUND: This study aimed to report the computer-enhanced robotic surgery experience of the authors' gynecologic oncology division.
  • METHODS: From January 2001 to August 2006, 41 patients underwent laparoscopic surgery by our gynecologic oncology service using a computer-enhanced surgical robot.
  • Of the 20 patients with gynecologic malignancies, 14 had cervical cancer.
  • A total of 21 patients had benign indications for surgery.
  • CONCLUSION: This case series is one of the first to report the use of a computer-enhanced surgical robot in gynecologic oncology.
  • [MeSH-major] Genital Neoplasms, Female / surgery. Gynecologic Surgical Procedures / instrumentation. Robotics / methods. Surgery, Computer-Assisted / methods
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Incidence. Middle Aged. Minimally Invasive Surgical Procedures / instrumentation. Neoplasm Staging. Postoperative Complications / epidemiology. Retrospective Studies. Risk Assessment. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17186433.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. De Gaetano AM, Calcagni ML, Rufini V, Valentini AL, Gui B, Giordano A, Bonomo L: Imaging of gynecologic malignancies with FDG PET-CT: case examples, physiologic activity, and pitfalls. Abdom Imaging; 2009 Nov;34(6):696-711
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of gynecologic malignancies with FDG PET-CT: case examples, physiologic activity, and pitfalls.
  • The utilization of 2-[fluorine 18] fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) in combination with computed tomography (CT) in the assessment of gynecologic malignancies has been rapidly growing in recent years; however, its role in clinical practice has yet to be established.
  • Increased uptake has also been reported in many benign pelvic processes and in premenopausal patients; endometrial activity changes cyclically, whereas increased ovarian uptake may be functional.
  • FDG PET-CT has an emerging role in staging nodal disease and in the evaluation of local recurrence or peritoneal spread of gynecologic malignancies and is also useful in monitoring response to therapy and in long-term follow-up.
  • FDG PET-CT is most suitable in patients with high tumor markers and negative or uncertain conventional imaging data.
  • [MeSH-major] Fluorodeoxyglucose F18. Genital Neoplasms, Female / radiography. Genital Neoplasms, Female / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Female. Humans. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / radionuclide imaging. Sensitivity and Specificity. Whole Body Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18791682.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 75
  •  go-up   go-down


12. Young RH: Dusting off another shelf: further comments on classic gynecologic pathology books of yesteryear. Int J Gynecol Pathol; 2005 Jan;24(1):100-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dusting off another shelf: further comments on classic gynecologic pathology books of yesteryear.
  • Selected outstanding books from the older literature on gynecologic pathology are reviewed with emphasis on drawing attention to the abundant helpful information and often outstanding illustrations that are worthy of review by present-day pathologists.
  • Each of them emphasizes the time-honored problem of mimicry of malignancy by diverse benign lesions or even aspects of normal histology.
  • Teilum's book contains a masterful account of the histopathology of germ cell tumors emphasizing a neoplasm with which his name will always be associated, the yolk sac tumor (endodermal sinus tumor).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15626924.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Khan N, Oriuchi N, Yoshizaki A, Kanuma T, Higuchi T, Endo K: Diagnostic accuracy of FDG PET imaging for the detection of recurrent or metastatic gynecologic cancer. Ann Nucl Med; 2005 Apr;19(2):137-45
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic accuracy of FDG PET imaging for the detection of recurrent or metastatic gynecologic cancer.
  • PURPOSE: This study evaluated the diagnostic role and accuracy of positron emission tomography (PET) using 2-[F-18]fluoro-2-deoxy-D-glucose (FDG) for the detection of tumor foci in patients with suspected recurrent or metastatic lesions of gynecologic cancers.
  • MATERIALS AND METHODS: FDG PET imaging was performed on 51 patients with a previous history of gynecologic cancer who were referred for a clinical suspicion of recurrent disease.
  • Malignant lesions accumulated significantly more FDG than the benign ones (the mean SUVs were 3.7 +/- 1.9 and 1.6 +/- 1.1, respectively, p = 0.004).
  • The sensitivity and specificity in correct identification of tumor recurrence or metastases using a threshold SUV 1.9 were 88.8% and 66.7% in contrast to the visual analysis (sensitivity 96.4%, specificity 50%) on a lesion-based analysis.
  • FDG PET was valuable when CT/MRI was negative or inconclusive, and in patients with elevated tumor marker levels as well as with normal tumor marker levels when recurrence was suspected clinically.
  • However, PET failed to visualize some small metastatic lesions in lung and bone, and showed falsely high FDG uptake in some benign lesions.
  • CONCLUSION: The results indicated that FDG PET is a reliable and accurate diagnostic method for detecting recurrent or metastatic gynecologic cancer particularly lymph node metastases.
  • [MeSH-major] Carcinoma / radionuclide imaging. Carcinoma / secondary. Fluorodeoxyglucose F18. Genital Neoplasms, Female / radionuclide imaging. Genital Neoplasms, Female / secondary. Neoplasm Recurrence, Local / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15909494.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


14. Wentling GK, Sevin BU, Geiger XJ, Bridges MD: Benign metastasizing leiomyoma responsive to megestrol: case report and review of the literature. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1213-7
Hazardous Substances Data Bank. MEGESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign metastasizing leiomyoma responsive to megestrol: case report and review of the literature.
  • Benign metastasizing leiomyoma (BML) is an unusual condition typically treated by surgical resection and hormonal therapy.
  • Total abdominal hysterectomy and right salpingo-oophorectomy revealed only leiomyomas and benign ovarian cysts.
  • A 21- x 18-mm residual area of neoplasm in the lung completely resolved 3 months after treatment with megestrol.
  • We present a rare case of BML in which the lung neoplasm responded to megestrol alone in the setting of intact ovarian function.
  • [MeSH-minor] Adult. Female. Gynecologic Surgical Procedures. Humans. Neoplasm Metastasis. Pneumonectomy. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343217.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EA6LD1M70M / Megestrol
  • [Number-of-references] 23
  •  go-up   go-down


15. Auner V, Sehouli J, Oskay-Oezcelik G, Horvat R, Speiser P, Zeillinger R: ABC transporter gene expression in benign and malignant ovarian tissue. Gynecol Oncol; 2010 May;117(2):198-201
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABC transporter gene expression in benign and malignant ovarian tissue.
  • METHODS: Real-time PCR was used to determine RNA expression levels of 9 ABC transporters in 50 benign tissue samples and 50 recurrent ovarian cancer samples.
  • RESULTS: Gene expression of four transporters (ABCC1, ABCC2, ABCC3, and ABCB3) was significantly elevated in recurrent cancer lesions compared to benign tissue.
  • A significant difference between primary and recurrent tumor tissue was found in all four genes.
  • Changes in gene expression between benign samples and primary lesions were minor and not relevant.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cystadenoma / genetics. Cystadenoma / metabolism. Cystadenoma / pathology. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Gene Expression. Humans. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Paclitaxel / administration & dosage. ROC Curve. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Inc. All rights reserved.
  • (PMID = 19922990.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 8N3DW7272P / Cyclophosphamide; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


16. Moon H, Park SJ, Lee HB, Kim SR, Choe YH, Chung MJ, Jin GY, Lee YC: Pulmonary benign metastasizing leiomyoma in a postmenopausal woman. Am J Med Sci; 2009 Jul;338(1):72-4
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary benign metastasizing leiomyoma in a postmenopausal woman.
  • Pulmonary benign metastasizing leiomyoma (BML) is a rare disease occurring predominantly in women of reproductive age and usually develops several years after the resection of a uterine leiomyoma.
  • We performed a gynecologic examination to identify the primary origin of the pulmonary smooth muscle tumors.
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Metastasis. Postmenopause

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19506459.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Onuma K, Dabbs DJ, Bhargava R: Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium. Int J Gynecol Pathol; 2008 Jul;27(3):418-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium.
  • Mammaglobin (MGB), a secretory protein belonging to the uteroglobin/Clara cell protein family, is a sensitive marker for breast carcinoma, but is also reported to be expressed in the female genital tract and its neoplasms.
  • Details of MGB expression pattern and its pathologic significance in the female genital tract have not been systematically studied.
  • To investigate the potential use of MGB in gynecologic pathology practice, we tested MGB expression by immunohistochemistry on 47 endocervical adenocarcinomas (whole tissue sections of 13 invasive and 35 in situ) and 55 endometrial carcinomas (39 endometrioid and 16 nonendometrioid represented on a single tissue microarray).
  • Endocervical adenocarcinoma in situ (AIS) showed either weak (predominantly) or moderate (occasionally) expression in about 40% of the cases in comparison with strong positivity in benign endocervical glandular epithelium.
  • Reduction of MGB staining was seen in transition from benign epithelium to AIS.
  • Most endocervical adenocarcinomas are negative for MGB, in contrast to mostly positive endometrioid endometrial adenocarcinomas, however, MGB expression alone is not specific enough to distinguish these 2 tumor types.
  • MGB may be a promising new adjunctive marker in gynecologic pathology.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Carcinoma in Situ / metabolism. Neoplasm Proteins / biosynthesis. Uterine Neoplasms / metabolism. Uteroglobin / biosynthesis. Uterus / metabolism
  • [MeSH-minor] Cervix Uteri / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Female. Humans. Immunohistochemistry. Mammaglobin A. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580321.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


18. Tsai HT, Tsai YM, Yang SF, Wu KY, Chuang HY, Wu TN, Ho CK, Lin CC, Kuo YS, Wu MT: Lifetime cigarette smoke and second-hand smoke and cervical intraepithelial neoplasm--a community-based case-control study. Gynecol Oncol; 2007 Apr;105(1):181-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lifetime cigarette smoke and second-hand smoke and cervical intraepithelial neoplasm--a community-based case-control study.
  • BACKGROUND: Both active cigarette smoking and human papillomavirus (HPV) infection are known risk factors for cervical intraepithelial neoplasm (CIN).
  • A total of 171 subjects with either their first case of inflammation (benign epithelial lesion) or > or = CIN1 by biopsy confirmation were assigned to a case group; 513 normal subjects with negative findings by Pap smears or biopsies were assigned to a control group.
  • [MeSH-minor] Adult. Biopsy. Case-Control Studies. Female. Humans. Middle Aged. Taiwan / epidemiology


19. Folpe AL, Mentzel T, Lehr HA, Fisher C, Balzer BL, Weiss SW: Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol; 2005 Dec;29(12):1558-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature.
  • This family of tumors includes angiomyolipoma (AML), clear cell sugar tumor of the lung (CCST), lymphangioleiomyomatosis (LAM), and very rare tumors in other locations.
  • Because non-AML/non-LAM PEComas are extremely rare and their natural history and prognostic features undefined, we present our experience with 26 PEComas of soft tissue and the gynecologic tract, the largest series to date.
  • The median patient age was 46 years (range, 15-97 years); there was a marked female predominance (22 females, 4 males).
  • Recurrence and/or metastasis was strongly associated tumor size > median size (8 cm), mitotic activity greater than 1/50 HPF, and necrosis.
  • We conclude that PEComas of soft tissue and gynecologic origin may be classified as "benign," "of uncertain malignant potential," or "malignant."
  • Small PEComas without any worrisome histologic features are most likely benign.
  • [MeSH-major] Biomarkers, Tumor / analysis. Epithelioid Cells / pathology. Genital Neoplasms, Female / pathology. Neoplasms, Connective and Soft Tissue / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Mitosis. Neoplasm Metastasis. Neoplasm Recurrence, Local. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome. Tumor Burden

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327428.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 56
  •  go-up   go-down


20. Paşaoğlu O, Ciftçi E, Tel N, Ozalp S, Acikalin MF: Benign clear cell adenofibroma of the ovary. A case report with literature review. Gynecol Obstet Invest; 2007;64(1):36-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for clear cell adenofibroma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign clear cell adenofibroma of the ovary. A case report with literature review.
  • Most clear cell neoplasms of the ovaries are carcinomas; benign and borderline clear cell tumors are uncommon.
  • To date, only 12 cases of benign clear cell adenofibroma have been reported in the literature.
  • Here we report a case of benign clear cell adenofibroma of the left ovary in a 51-year-old postmenopausal woman.
  • In this article we discussed the criteria for the diagnosis of benign and borderline clear cell adenofibromas and reviewed the literature.
  • [MeSH-minor] Biopsy, Needle. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovariectomy / methods. Pelvic Pain / diagnosis. Pelvic Pain / etiology. Postmenopause. Risk Assessment. Treatment Outcome. Uterine Hemorrhage / diagnosis. Uterine Hemorrhage / etiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for adenofibroma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17202822.001).
  • [ISSN] 1423-002X
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 8
  •  go-up   go-down


21. Jordan SJ, Green AC, Whiteman DC, Webb PM, Australian Ovarian Cancer Study Group: Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum? Gynecol Oncol; 2007 Nov;107(2):223-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?
  • OBJECTIVE: Some molecular and histological evidence suggests that mucinous epithelial ovarian cancers develop via a sequence from benign tumor through borderline tumor to invasive cancer.
  • Such a sequence would predict some shared risk factors between the different tumor types.
  • To investigate this, we examined risk factors for benign, borderline and invasive mucinous ovarian tumors.
  • Women with benign (n=133), borderline (n=147) and invasive (n=43) mucinous tumors of the ovary and women from the general population (n=1487) completed comprehensive health and lifestyle questionnaires.
  • RESULTS: Although parity was inversely related to risk of benign, borderline and invasive tumors, increasing numbers of births did not further decrease risk of any of the tumor types.
  • However, 20 or more pack-years of smoking was associated with a more than twofold increase in risk of all three tumor types (OR=2.7, 95% CI 1.6-4.4 for benign tumors; OR=2.7, 95% CI 1.7-4.4 for borderline tumors; and OR=2.1, 95% CI 0.9-5.0 for invasive cancers) compared to never smoking.
  • Furthermore, patterns of risk factors across benign, borderline and invasive mucinous ovarian tumors are generally consistent with an adenoma-to-carcinoma sequence as the developmental pathway for this subtype of ovarian cancer.
  • [MeSH-minor] Adult. Aged. Australia. Case-Control Studies. Cell Transformation, Neoplastic / pathology. Female. Health Status. Humans. Life Style. Middle Aged. Neoplasm Invasiveness. Odds Ratio. Reproductive History. Risk Assessment. Risk Factors. Smoking / adverse effects. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17662378.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


22. Shibata K, Kajiyama H, Mizokami Y, Ino K, Nomura S, Mizutani S, Terauchi M, Kikkawa F: Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia. Gynecol Oncol; 2005 Jul;98(1):11-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
  • The authors evaluated P-LAP and GLUT4 expression in benign, borderline, and malignant ovarian epithelia.
  • METHODS: Histologic sections of formalin-fixed, paraffin-embedded specimens from 11 patients with benign serous or mucinous cystadenomas, 14 patients with serous or mucinous borderline tumors, and 80 patients with epithelial-ovarian adenocarcinomas (29 serous, 17 endometrioid, 14 mucinous, and 20 clear cell adenocarcinomas) were stained for P-LAP and GLUT4 using each polyclonal antibody.
  • RESULTS: P-LAP immunoreactivity was detected in 2 of 11 benign cystadenomas.
  • None of the 11 benign ovarian tumors showed any immunoreactivity for GLUT4.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Growth Processes / physiology. Cell Line, Tumor. Epithelium / enzymology. Epithelium / metabolism. Female. Glucose Transporter Type 4. Humans. Middle Aged. Neoplasm Invasiveness. Ovarian Diseases / enzymology. Ovarian Diseases / metabolism. Ovarian Diseases / pathology. Transfection

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15907336.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 4; 0 / Monosaccharide Transport Proteins; 0 / Muscle Proteins; 0 / SLC2A4 protein, human; EC 3.4.11.3 / Cystinyl Aminopeptidase; EC 3.4.11.3 / leucyl-cystinyl aminopeptidase
  •  go-up   go-down


23. de Ruiter GC, Scheithauer BW, Amrami KK, Spinner RJ: Benign metastasizing leiomyomatosis with massive brachial plexus involvement mimicking neurofibromatosis type 1. Clin Neuropathol; 2006 Nov-Dec;25(6):282-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign metastasizing leiomyomatosis with massive brachial plexus involvement mimicking neurofibromatosis type 1.
  • We report the case of a patient who presented with right arm and shoulder pain due to compression of the infraclavicular brachial plexus due to benign metastasizing leiomyomatosis (BML).
  • The diagnosis of BML was not obvious due to its rare nature, the patient's not detailing the specifics of her gynecologic history of having undergone resection of a large uterine leiomyoma and followed by disseminated pelvic leiomyomatous nodules, histologic misinterpretation of an extrauterine lesion of the spine and the brachial plexus as a neurofibroma and the radiologic diagnosis of lung nodules as being "non-specific" in nature.
  • [MeSH-major] Brachial Plexus / pathology. Brachial Plexus Neuropathies / etiology. Brachial Plexus Neuropathies / pathology. Leiomyoma / pathology. Neoplasm Metastasis / pathology. Neurofibromatosis 1 / diagnosis. Peripheral Nervous System Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Decompression, Surgical. Diagnosis, Differential. Diagnostic Errors / prevention & control. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Pain / etiology. Pain / pathology. Pain / physiopathology. Spinal Neoplasms / pathology. Spinal Neoplasms / physiopathology. Treatment Outcome


24. Takeuchi M, Matsuzaki K, Nishitani H: Diffusion-weighted magnetic resonance imaging of endometrial cancer: differentiation from benign endometrial lesions and preoperative assessment of myometrial invasion. Acta Radiol; 2009 Oct;50(8):947-53
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted magnetic resonance imaging of endometrial cancer: differentiation from benign endometrial lesions and preoperative assessment of myometrial invasion.
  • BACKGROUND: Uterine endometrial cancer is the most common gynecologic malignancy, and benign endometrial hyperplasia or polyps should be differentiated from endometrial cancer.
  • PURPOSE: To verify the feasibility of diffusion-weighted magnetic resonance imaging (DWI) to distinguish benign and malignant endometrial lesions, and to evaluate myometrial invasion of endometrial cancer.
  • MATERIAL AND METHODS: Sixty-seven endometrial lesions including 45 cancers and 22 benign lesions (hyperplasia and polyps) were evaluated by DWI with apparent diffusion coefficient (ADC) measurement.
  • RESULTS: The ADC values (x10(-3) mm(2)/s) in cancer and benign lesions were 0.84+/-0.19 and 1.58+/-0.36, respectively (P<0.01).
  • Coexisting adenomyosis and infiltrative myometrial invasion caused staging errors on gadolinium-enhanced T1-weighted images, whereas DWI could demonstrate the tumor extent correctly.
  • CONCLUSION: DWI provides helpful information in evaluating benign and malignant endometrial lesions.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Contrast Media. Diagnosis, Differential. Feasibility Studies. Female. Gadolinium. Humans. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19724949.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


25. Begum FD, Høgdall E, Kjaer SK, Blaakaer J, Christensen IJ, Christensen L, Høgdall C: Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors. Gynecol Oncol; 2009 May;113(2):221-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
  • Another aim is to find new diagnostic markers, which may select patients at high risk for OC for quick referral to highly specialized centers in gynecologic oncology.
  • METHODS: The potential ability of the markers to discriminate between the four groups (208 benign ovarian tumor, 153 borderline ovarian tumor (BOT), 445 OC and 1333 age matched controls) in OC screening was examined.
  • We also constructed a risk assessment index (RAI) for discrimination between tumor groups based on these variables and menopausal status.
  • A very high probability of having OC or a benign tumor, respectively, was predicted by the RAI.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Lectins, C-Type / blood. Ovarian Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Ovarian Diseases / blood. Ovarian Diseases / diagnosis. Ovarian Diseases / pathology. Postmenopause / blood. Premenopause / blood. Preoperative Care. Risk Assessment

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19261323.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Lectins, C-Type; 109489-77-2 / tetranectin
  •  go-up   go-down


26. Liu YN, Ye X, Cheng HY, Cheng YX, Fu TY, Chen J, Chang XH, Cui H: [Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors]. Zhonghua Fu Chan Ke Za Zhi; 2010 May;45(5):363-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors].
  • OBJECTIVE: To investigate the value of human epididymis secretory protein 4(HE4) combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian malignant tumor.
  • METHODS: The level of HE4 and CA125 were measured by enzyme-linked immunosorbent assay (ELISA) in the serum specimens of 46 cases in endometriosis cyst group, 36 cases in malignant ovarian tumor group, 60 cases in benign ovarian diseases and 50 women in healthy women group.
  • (1) HE4: the median levels of HE4 were 52.4, 51.0, 50.0 pmol/L in group of endometriosis, normal control and benign ovarian tumor, which didn't show statistical difference.
  • However, HE4 was 507.5 pmol/L in ovarian cancer group, which was significantly higher than those of 3 groups (P<0.05). (2) CA125: there were significant different in median level of CA125 was observed as 743.0 kU/L in ovarian cancer, 84.9 kU/L in endoemtriosis, 15.4 kU/L in benign ovarian disease, and 11.5 kU/L in healthy women (P<0.05). (3) The single assay: when compared with that in endometriosis group, receiver operating characteristic area under the curve (ROC-AUC) were 0.933 in HE4 alone and 0.821 in CA125 alone assay in ovarian cancer group.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / blood. Case-Control Studies. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. ROC Curve. Sensitivity and Specificity. Young Adult

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646446.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Epididymal Secretory Proteins
  •  go-up   go-down


27. Downs LS Jr, Lima PH, Bliss RL, Blomquist CH: Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and epithelial ovarian cancer. J Soc Gynecol Investig; 2005 Oct;12(7):539-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and epithelial ovarian cancer.
  • OBJECTIVE: Cathepsins B (CB) and D (CD) belong to a family of proteases felt to be important in tumor metastasis and invasion.
  • Tissue specimens were divided into four groups: normal ovary, benign neoplasm, early-stage (I/II) cancer, and late-stage (III/IV) cancer.
  • CONCLUSIONS: CB activity is associated with invasive ovarian neoplasm.
  • [MeSH-minor] Female. Humans. Isoenzymes. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202931.001).
  • [ISSN] 1556-7117
  • [Journal-full-title] Journal of the Society for Gynecologic Investigation
  • [ISO-abbreviation] J. Soc. Gynecol. Investig.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 3.4.22.1 / Cathepsin B; EC 3.4.23.5 / Cathepsin D
  •  go-up   go-down


28. Rettenmaier M, Epstein HD, Abaid LN, Bechtol KA, Goldstein BH: Leiomyosarcoma with synchronous clear cell ovarian carcinoma. Onkologie; 2010;33(12):695-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Uterine leiomyomas are typically considered benign lesions.
  • In November 2009, she presented to our gynecologic oncology service with a complex mass.
  • Following surgery, the patient was diagnosed with a 16 cm ovarian mass and a synchronous leiomyosarcoma; the latter neoplasm appeared to originate from a previously resected uterine leiomyoma.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Cell Transformation, Neoplastic / pathology. Chemotherapy, Adjuvant. Colonic Neoplasms / pathology. Colonic Neoplasms / secondary. Colonic Neoplasms / surgery. Female. Humans. Hysterectomy. Intestinal Neoplasms / pathology. Intestinal Neoplasms / secondary. Intestinal Neoplasms / surgery. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Omentum / pathology. Omentum / surgery. Ovariectomy. Salpingectomy. Uterus / pathology


29. Bristow RE, Nugent AC, Zahurak ML, Khouzhami V, Fox HE: Impact of surgeon specialty on ovarian-conserving surgery in young females with an adnexal mass. J Adolesc Health; 2006 Sep;39(3):411-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the patterns of surgical care among pediatric and adolescent females undergoing operative intervention for an adnexal mass with particular attention toward factors associated with ovarian-conserving surgery and access to gynecologic care.
  • METHODS: All female patients aged < or = 18 years undergoing surgery for an adnexal mass between January 1, 1991 and December 31, 2002 were retrospectively identified and demographic, operative, and pathologic data abstracted.
  • Logistic regression analyses were used to identify factors independently associated with ovarian-conserving surgery and access to gynecologic care.
  • A malignant ovarian neoplasm was present in 14.6% of cases.
  • The presence of a gynecologic surgeon, compared to other surgical specialties, was statistically significantly and independently associated with ovarian-conserving surgery (odds ratio [OR] 8.71, 95% confidence interval [CI] 2.12-41.41, p = .001).
  • Post-menarchal status and age > or = 16 years were the characteristic most predictive of access to gynecologic surgical care.
  • CONCLUSIONS: In pediatric and adolescent patients, operative intervention for an adnexal mass is significantly more likely to result in ovarian conservation when performed by a gynecologic surgeon.
  • For such patients, improved access to gynecologic consultation prior to surgical intervention may reduce the number of patients subjected to oophorectomy for benign conditions.
  • [MeSH-major] Gynecologic Surgical Procedures / methods. Ovarian Cysts / surgery. Practice Patterns, Physicians'
  • [MeSH-minor] Adnexal Diseases / surgery. Adolescent. Child. Child, Preschool. Female. Health Services Accessibility. Humans. Infant. Multivariate Analysis. Ovarian Diseases / surgery. Ovarian Neoplasms / surgery. Ovariectomy. Retrospective Studies. Suction. Torsion Abnormality

  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919804.001).
  • [ISSN] 1879-1972
  • [Journal-full-title] The Journal of adolescent health : official publication of the Society for Adolescent Medicine
  • [ISO-abbreviation] J Adolesc Health
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


30. Powell JL, Cunill ES, Gajewski WH, Novotny DB: Sarcoidosis mimicking recurrent endometrial cancer. Gynecol Oncol; 2005 Dec;99(3):770-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Sarcoidosis is a multisystem disease and can be confused with benign or malignant tumors.
  • In patients with recurrent gynecologic cancer, liver and intrathoracic lesions should undergo a biopsy to rule in metastatic malignancy, as clinical findings and CAT scan results may represent other disease processes.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Sarcoidosis / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Sarcoidosis.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168469.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Lowe MP, Chamberlain DH, Kamelle SA, Johnson PR, Tillmanns TD: A multi-institutional experience with robotic-assisted radical hysterectomy for early stage cervical cancer. Gynecol Oncol; 2009 May;113(2):191-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A multi-institutional robotic surgical consortium consisting of five board-certified gynecologist oncologist in distinct geographical regions of the United States was created to evaluate the utility of robotics for gynecologic surgery (benign and malignant).
  • Between April 2003 and August 2008, a total of 835 patients underwent robotic surgery for benign gynecologic disorders and/or gynecologic malignancies by a surgeon in the consortium.
  • RESULTS: From a database of 835 patients who underwent robotic surgery by a gynecologic oncologist, a total of 42 patients who underwent a robotic-assisted type II (n=10) or type III (n=32) radical hysterectomy for early stage cervical cancer were identified.
  • [MeSH-minor] Adult. Female. Humans. Hysterectomy. Laparoscopy. Neoplasm Staging. Retrospective Studies. Robotics. Treatment Outcome

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249082.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


32. Canis M, Jardon K, Niro J, Rabischong B, Bourdel N, Botchorishvili R, Pouly JL, Mage G: [Endoscopic management of gynecological malignancies: an update. 2007]. Bull Acad Natl Med; 2007 Oct;191(7):1357-65; discussion 1365-6
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All the different surgical procedures used to treat gynecologic cancers have already been performed with the endoscopic approach.
  • Animal studies suggest that the risk of tumor dissemination in the non traumatized peritoneum may be higher after pneumoperitoneum than after laparotomy, and they also show the importance of the surgeon's experience and technique.
  • By controlling these parameters we may, in future, be able to create a peritoneal environment suitable for oncologic indications and thereby prevent or minimize the risk of peritoneal dissemination and postoperative tumor growth.
  • In contrast, restaging of early ovarian cancer initially managed as a benign mass is a good indication for the laparoscopic approach.
  • Training in endoscopic oncological techniques will be a major challenge in the field of gynecologic surgery in coming years.
  • [MeSH-major] Endoscopy / methods. Genital Neoplasms, Female / surgery. Gynecologic Surgical Procedures / methods
  • [MeSH-minor] Animals. Carcinoma / secondary. Carcinoma / surgery. Endometrial Neoplasms / surgery. Female. Humans. Neoplasm Seeding. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Peritoneal Neoplasms / secondary. Pneumoperitoneum, Artificial / adverse effects. Pneumoperitoneum, Artificial / methods. Swine. Uterine Cervical Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447057.001).
  • [ISSN] 0001-4079
  • [Journal-full-title] Bulletin de l'Académie nationale de médecine
  • [ISO-abbreviation] Bull. Acad. Natl. Med.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 30
  •  go-up   go-down


33. Suh-Burgmann E: Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecol Oncol; 2006 Dec;103(3):841-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study.
  • OBJECTIVES: To examine outcomes in women treated with conservative surgery for borderline ovarian tumor in a large population-based cohort with long-term follow-up.
  • METHODS: Women treated by conservative surgery for borderline tumor of the ovary from 1982-2004 within a large HMO setting were identified using electronic and tumor registry data.
  • The indications for and outcomes from any subsequent gynecologic surgery and the risk of recurrent ovarian borderline and malignant tumor were determined.
  • There were 21 recurrences with borderline tumor (11%) with a median time to first recurrence of 4.7 years; women treated by cystectomy recurred three times more often compared to women treated by oophorectomy (23% versus 7%).
  • During long-term follow-up, 19% of patients eventually underwent complete removal of ovarian tissue: in 8%, the surgery was prophylactic, in 5%, surgery was done for benign pathology, and in 6% for recurrent disease.
  • CONCLUSIONS: In this population-based HMO setting, 11% of women treated with conservative surgery for borderline tumor recurred; however, half of these recurrences were successfully managed by repeat conservative surgery, with only 6% of women overall needing eventual complete removal of ovaries for recurrent disease.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. California / epidemiology. Child. Cohort Studies. Disease-Free Survival. Female. Fertility. Gynecologic Surgical Procedures / methods. Gynecologic Surgical Procedures / utilization. Health Maintenance Organizations. Humans. Medical Records. Middle Aged. Neoplasm Staging. Postoperative Complications. Registries. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793124.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Chen YJ, Yuan CC, Chow KC, Wang PH, Lai CR, Yen MS, Wang LS: Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. Gynecol Oncol; 2005 Apr;97(1):110-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Normal ovarian tissues were obtained from patients with benign gynecologic diseases (n = 14).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. DNA, Neoplasm / genetics. Drug Resistance, Neoplasm. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790446.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / RNA, Messenger; EC 1.- / Oxidoreductases; EC 1.3.1.20 / trans-1,2-dihydrobenzene-1,2-diol dehydrogenase; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


35. Cankovic M, Gaba AR, Meier F, Kim W, Zarbo RJ: Detection of non-maternal components of gestational choriocarcinoma by PCR-based microsatellite DNA assay. Gynecol Oncol; 2006 Nov;103(2):614-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: Benign and malignant tissues, preserved in paraffin blocks and separated by microdissection, were examined using a commercial PCR-based tissue identity assay (ABI AmpFlSTR Profiler Plus Kit and ABI 377 DNA sequencer) to detect genetic profiles of 9 microsatellite markers, along with X and Y chromosome markers.
  • Controls included eight non-germ cell reproductive tract tumors and two hydatidiform moles.
  • The neoplasm previously classified as a non-gestational choriocarcinoma was demonstrated to be of maternal origin, as were the non-germ cell reproductive tract tumors.
  • [MeSH-minor] Alleles. Case-Control Studies. Choriocarcinoma, Non-gestational / genetics. DNA, Neoplasm / genetics. Fallopian Tube Neoplasms / genetics. Female. Humans. Lung Neoplasms / genetics. Ovarian Neoplasms / genetics. Pregnancy

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740299.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


36. Baba T, Kariya M, Higuchi T, Mandai M, Matsumura N, Kondoh E, Miyanishi M, Fukuhara K, Takakura K, Fujii S: Neuropilin-1 promotes unlimited growth of ovarian cancer by evading contact inhibition. Gynecol Oncol; 2007 Jun;105(3):703-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While there are some reports of NRP-1 expression in ovarian neoplasm, those results differ in pattern of its expression and its role in ovarian cancer is still unclear.
  • RESULTS: NRP-1 expression was found to be enhanced in ovarian cancer compared with ovarian surface epithelium (OSE), benign adenoma and tumors of low malignant potential.
  • [MeSH-minor] Cell Adhesion / physiology. Cell Count. Cell Growth Processes / physiology. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. RNA, Small Interfering / genetics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17376520.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 144713-63-3 / Neuropilin-1
  •  go-up   go-down


37. Loizzi V, Cormio G, Resta L, Fattizzi N, Vicino M, Selvaggi L: Pseudo-Meigs syndrome and elevated CA125 associated with struma ovarii. Gynecol Oncol; 2005 Apr;97(1):282-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Struma ovarii is a rare form of ovarian neoplasm composed entirely and predominantly of thyroid tissue.
  • CASE: We report an unusual presentation of a postmenopausal woman with benign struma ovarii associated with pseudo-Meigs syndrome, hypertiroidism, and elevated CA125 serum level, and a large complex right pelvic mass thereby mimicking an ovarian cancer.
  • [MeSH-major] CA-125 Antigen / blood. Carcinoid Tumor / blood. Meigs Syndrome / blood. Ovarian Neoplasms / blood. Struma Ovarii / blood
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Hyperthyroidism / blood

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790478.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


38. Mukonoweshuro P, Oriowolo A: Stromal osseous metaplasia in a low-grade ovarian adenocarcinoma. Gynecol Oncol; 2005 Oct;99(1):222-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: The patient, a 66-year-old P3 G3 white female, had a past history of stage 1c left ovarian, well-differentiated endometrioid adenocarcinoma removed in 1981.
  • The tumor recurred 21 years later with prominent stromal osseous metaplasia that had not been present in the primary.
  • CONCLUSION: Benign osseous metaplasia in ovarian tumors is rare and its histogenesis remains unclear.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Neoplasm Recurrence, Local / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Metaplasia

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16023183.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Bradley WH, Lima PH, Rodgers L, Blomquist CH, Downs LS: Endometrial carcinoma expresses an increased cathepsin B/D ratio. Gynecol Oncol; 2008 Jan;108(1):84-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Cathepsins B and D belong to a family of proteases involved in tumor invasion and metastasis.
  • As such they may function as biomarkers for the aggressiveness of a given tumor.
  • 4 groups were established: benign tissue, stage I/grade 1, stage i/grade 3, and stage IIIC/any grade.
  • RESULTS: A significantly increased level of cathepsin B activity was seen in malignant tissue specimens when compared to benign tissue.
  • The cathepsin B/D ratio confirmed and was required to detect the significance of this distinction for each malignant group when compared to benign samples.
  • CONCLUSIONS: Malignant endometrium displays increased cathepsin B activity when compared benign samples.
  • The cathepsin B/D ratio is increased for each of the malignant groups studied when compared directly to benign endometrium.
  • This ratio may serve to distinguish malignant from benign tumor samples and may be a constitutive change in the malignant transformation.
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980407.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.22.1 / Cathepsin B; EC 3.4.23.5 / Cathepsin D
  •  go-up   go-down


40. Leiserowitz GS: Managing ovarian masses during pregnancy. Obstet Gynecol Surv; 2006 Jul;61(7):463-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The etiologies of ovarian masses are reflective of the patient's age; and, therefore, benign entities such as functional ovarian cysts, benign cystic teratomas, and serous cystadenomas predominate.
  • Morphologic criteria more accurately identify benign cysts compared with malignant tumors.
  • Tumor markers are used primarily to monitor disease status after treatment rather than establish the ovarian tumor diagnosis as a result of lack of specificity, because several markers can be elevated inherent to the pregnancy itself (eg, CA-125, beta-hCG).
  • The extent of surgery depends on the intraoperative diagnosis of a benign versus a malignant tumor.
  • Conservative surgery is appropriate for benign masses and borderline ovarian tumors.
  • [MeSH-minor] Female. Humans. Laparoscopy / methods. Neoplasm Staging. Pregnancy. Pregnancy Outcome. Prognosis. Risk Factors. Sensitivity and Specificity


41. Yilmaz I, Baloglu H, Haholu A, Berber U, Yildirim S, Ergur AR: Objective risk definition for endometrial lesion spectrum: a diagnostic algorithm. Gynecol Oncol; 2007 May;105(2):451-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The study was carried out on 20 benign endometria, 35 hyperplasias, and 20 adenocarcinoma cases.
  • RESULTS: All benign tissues had polyclonal (PC), whereas all malignant tissues had monoclonal (MC) glandular epithelium.
  • [MeSH-minor] Female. Humans. Neoplasm Staging. PTEN Phosphohydrolase / biosynthesis. PTEN Phosphohydrolase / genetics. Risk Assessment. Sensitivity and Specificity. Tissue Array Analysis


42. Chang W, Oiseth SJ, Orentlicher R, Agarwal G, Yahr LJ, Cayten CG: Bilateral sclerosing stromal tumor of the ovaries in a premenarchal girl. Gynecol Oncol; 2006 May;101(2):342-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral sclerosing stromal tumor of the ovaries in a premenarchal girl.
  • BACKGROUND: Sclerosing stromal tumor of the ovary is a rare benign neoplasm that is usually unilateral in menstruating women with a mean age of 27.
  • CASE: An 11-year-old girl presented with asymptomatic bilateral sclerosing stromal tumor of the ovaries prior to menarche.
  • CONCLUSION: We herein report a unique case of bilateral sclerosing stromal tumor of the ovaries arising in a premenarchal girl.
  • [MeSH-minor] Child. Female. Humans. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16403568.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K: Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol Oncol; 2005 Feb;96(2):516-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the clinical relevance of serum secretory leukocyte protease inhibitor (SLPI) levels in distinguishing patients with ovarian cancers from those with benign ovarian cysts, we determined concentrations with reference to the FIGO stage and other clinical characteristics.
  • METHODS: Preoperative serum SLPI levels were measured in women with invasive epithelial ovarian cancer (n = 55), benign ovarian cysts (n = 25), or normal controls (n = 38) using an enzyme-linked immunosorbent assay (ELISA).
  • RESULTS: The serum SLPI concentration was significantly elevated in the ovarian cancer patients (median 67 ng/ml, interquartile range 26-124 ng/ml) as compared to the benign cyst patients (37 and 25-66 ng/ml) or healthy women (32 and 25-43 ng/ml).
  • Using an SLPI cutoff of 50 ng/ml and a CA125 cutoff of 30 units/ml, with both markers elevated the sensitivity was 95%, the specificity was 100%, the positive predictive value was 100%, and the negative predictive value was 89% between the malignant and benign cyst patients.
  • CONCLUSION: Serum SLPI levels could be useful for differentiating benign ovarian cysts from malignancies and to improve the specificity of diagnosis.
  • [MeSH-minor] CA-125 Antigen / blood. Case-Control Studies. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. Ovarian Cysts / blood. Ovarian Cysts / diagnosis. Proteinase Inhibitory Proteins, Secretory. Secretory Leukocyte Peptidase Inhibitor. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661245.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Proteinase Inhibitory Proteins, Secretory; 0 / Proteins; 0 / SLPI protein, human; 0 / Secretory Leukocyte Peptidase Inhibitor
  •  go-up   go-down


44. Ray K, Rocconi RP, Novak L, Straughn JM Jr: Recurrence of endometrial adenocarcinoma in a prior Bartholin's cyst marsupialization incision. Gynecol Oncol; 2006 Nov;103(2):749-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: A 53-year-old woman underwent a dual procedure of a marsupialization of a benign bartholin's cyst with a hysteroscopic dilation and curettage for postmenopausal bleeding and received the diagnosis of endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Seeding
  • [MeSH-minor] Bartholin's Glands / surgery. Cysts / surgery. Dilatation and Curettage / adverse effects. Female. Humans. Hysterectomy / adverse effects. Middle Aged. Vaginal Diseases / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16842845.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Javitt MC: ACR Appropriateness Criteria on staging and follow-up of ovarian cancer. J Am Coll Radiol; 2007 Sep;4(9):586-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian cancer is the most common cause of cancer death from gynecologic malignancy in women.
  • The diagnosis and treatment of ovarian cancer are especially challenging because of the high prevalence of benign disease in the ovaries and the tendency for late presentation of ovarian cancer after it has spread.
  • [MeSH-major] Diagnostic Imaging. Neoplasm Staging / methods. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] CA-125 Antigen / blood. Female. Humans

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17845961.001).
  • [ISSN] 1558-349X
  • [Journal-full-title] Journal of the American College of Radiology : JACR
  • [ISO-abbreviation] J Am Coll Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  • [Number-of-references] 35
  •  go-up   go-down


46. Duggal R, Nijhawan R, Aggarwal N, Sikka P: Mullerian adenosarcoma (heterologous) of the cervix with sarcomatous overgrowth: a case report with review of literature. J Gynecol Oncol; 2010 Jun;21(2):125-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mullerian adenosarcoma is a rare biphasic malignant neoplasm of the cervix characterized by an admixture of benign epithelial elements and a malignant sarcomatous stromal component, which may be either homologous or heterologous.
  • Because MASO with heterologous elements seems to appear at the earliest stages of reproductive lifespan in women, and have an uncertain malignant potential, gynecologists and pathologists should be aware and think about the possibility of this tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1990 Apr;21(4):363-81 [2156771.001]
  • [Cites] Am J Surg Pathol. 1989 Jan;13(1):28-38 [2535774.001]
  • [Cites] Cancer. 1974 Oct;34(4):1138-49 [4371193.001]
  • [Cites] J Clin Pathol. 2008 Sep;61(9):1041-4 [18552169.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):256-60 [17292949.001]
  • [Cites] Ups J Med Sci. 2007;112(1):67-72 [17578809.001]
  • [Cites] Int J Gynecol Cancer. 2004 Sep-Oct;14(5):1024-9 [15361219.001]
  • (PMID = 20613904.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2895712
  • [Keywords] NOTNLM ; Heterologous / Mullerian adenosarcoma / Sarcomatous overgrowth / Uterine cervix
  •  go-up   go-down


47. Timofeev J, Galgano MT, Stoler MH, Lachance JA, Modesitt SC, Jazaeri AA: Appendiceal pathology at the time of oophorectomy for ovarian neoplasms. Obstet Gynecol; 2010 Dec;116(6):1348-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the prevalence of appendiceal pathology in women undergoing surgery for a suspected ovarian neoplasm and the predictive value of intraoperative findings to determine the need for appendectomy at the time of surgery.
  • METHODS: Retrospective analysis of patients who underwent oophorectomy and appendectomy during the same surgical procedures at the University of Virginia Health System from 1992 to 2007.
  • Observations were stratified based on the nature (benign, borderline, or malignant) and histology (serous compared with mucinous) of the ovarian neoplasm, frozen compared with final pathological diagnosis, and the gross appearance of the appendix.
  • RESULTS: Among the 191 patients identified, frozen section was consistent with seven mucinous and 35 serous carcinomas, 16 serous and 33 mucinous borderline tumors, 71 mucinous and serous cystadenomas, and 29 cases of suspected metastatic tumor from a gastrointestinal primary.
  • Appendectomy is recommended when frozen section diagnosis is mucinous or serous ovarian carcinoma, borderline tumor or metastatic carcinoma of suspected gastrointestinal origin.
  • [MeSH-minor] Adult. Appendiceal Neoplasms / diagnosis. Appendiceal Neoplasms / secondary. Appendiceal Neoplasms / surgery. Appendix / pathology. Cecal Diseases / complications. Cecal Diseases / diagnosis. Cecal Diseases / surgery. Female. Frozen Sections. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21099601.001).
  • [ISSN] 1873-233X
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Granovsky-Grisaru S, Zaidoun S, Grisaru D, Yekel Y, Prus D, Beller U, Bar-Shavit R: The pattern of Protease Activated Receptor 1 (PAR1) expression in endometrial carcinoma. Gynecol Oncol; 2006 Dec;103(3):802-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While the role of either soluble or matrix-immobilized protease in tumor invasion is well established, the part of cell surface PARs is beginning to emerge.
  • CONCLUSIONS: PAR1 over-expression is selectively confined to the highly aggressive, high-grade endometrial carcinoma and absent in tissue obtained from benign endometrium or low-grade endometrial cancer.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Receptor, PAR-1 / metabolism
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Neoplasm Staging. RNA, Messenger / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875721.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptor, PAR-1
  •  go-up   go-down


49. Leiser AL, Anderson SE, Nonaka D, Chuai S, Olshen AB, Chi DS, Soslow RA: Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma. Gynecol Oncol; 2006 Apr;101(1):86-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A tissue microarray representing 36 uterine leiomyosarcomas and 19 uterine leiomyomas was created with 3 representative cores from each tumor.
  • In a multivariate analysis, tumor stage was the only independent significant prognostic factor (P = 0.002).
  • CONCLUSION: The significant differential expression of apoptotic and cell cycle regulatory proteins in uterine leiomyosarcoma as compared to benign smooth muscle tumors suggests that pathways involving these proteins may be important in the development of malignant disease and, therefore, could be potential targets for molecular therapies.
  • [MeSH-major] Apoptosis / physiology. Biomarkers, Tumor / biosynthesis. Cell Cycle / physiology. Cell Cycle Proteins / biosynthesis. Leiomyosarcoma / metabolism. Leiomyosarcoma / pathology. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16289259.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins
  •  go-up   go-down


50. Manolis T, Lee YC, Temkin S, Hellman M, Nacharaju VL, Abulafia O: NAD dependent 11beta-hydroxysteroid dehydrogenase activity in human endometrium and endometrial tumors. Gynecol Obstet Invest; 2006;62(2):103-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: NAD dependent 11beta-HSD activity was determined in endometrial tissue obtained from patients undergoing hysterectomy for benign or malignant disease (endometroid, serous and carcinosarcomas).
  • [MeSH-minor] Female. Humans. Hysterectomy. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16645302.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 1.1.1.146 / 11-beta-Hydroxysteroid Dehydrogenase Type 2
  •  go-up   go-down


51. Kong F, Nicole White C, Xiao X, Feng Y, Xu C, He D, Zhang Z, Yu Y: Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer. Gynecol Oncol; 2006 Feb;100(2):247-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • New biomarkers that individually or in combination improve the diagnostic performance of existing tumor markers are critically needed.
  • The first set of patients included 21 ovarian cancers, 18 benign diseases, and 20 normal patients.
  • The second set included 32 ovarian cancers, 30 benign ovarian diseases, and 30 age-matched healthy controls.
  • [MeSH-major] Biomarkers, Tumor / blood. Blood Proteins / analysis. Neoplasm Proteins / blood. Ovarian Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Computational Biology. Female. Humans. Middle Aged. Neoplasm Staging. Proteomics / methods. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16229881.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


52. Hsu TL, Changchien CC, Huang CC, Lin H: Angioleiomyoma originating from the ovary of an eleven-year-old premenarchal girl. Gynecol Obstet Invest; 2008;65(4):262-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Angioleiomyoma (ALM) is a rare, benign neoplasm involving the peripheral soft tissues.
  • The final pathologic report of the resected tumor was consistent with an ALM.
  • [MeSH-minor] Adolescent. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • [CommentIn] Gynecol Obstet Invest. 2010;70(1):8-10 [20130412.001]
  • (PMID = 18196910.001).
  • [ISSN] 1423-002X
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


53. Piura B, Rabinovich A, Sinelnikov I, Delgado B: Tailgut cyst initially misdiagnosed as ovarian tumor. Arch Gynecol Obstet; 2005 Oct;272(4):301-3
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tailgut cyst initially misdiagnosed as ovarian tumor.
  • It is usually benign and located in the retrorectal/presacral space.
  • The initial diagnosis was neoplasm of the right ovary.
  • [MeSH-minor] Diagnosis, Differential. Female. Histocytochemistry. Humans. Hysterectomy. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16041543.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


54. O'Meara AC, Giger OT, Kurrer M, Schaer G: Case report: Recurrence of a uterine tumor resembling ovarian sex-cord tumor. Gynecol Oncol; 2009 Jul;114(1):140-2
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: Recurrence of a uterine tumor resembling ovarian sex-cord tumor.
  • BACKGROUND: Uterine tumors resembling ovarian sex-cord tumors are very rare uterine neoplasias that generally behave in a benign manner.
  • We report the case of a uterine tumor resembling an ovarian sex-cord tumor that recurred after hysterectomy.
  • Ultrasound examination showed a heterogeneous uterine tumor composed of cystic and solid parts.
  • Because of the patient's desire to preserve fertility, tumor resection was scheduled.
  • The final histological diagnosis was uterine tumor resembling ovarian sex-cord tumor.
  • CONCLUSION: Although uterine tumors resembling ovarian sex-cord tumors generally behave in a benign manner, they may in rare cases metastasize.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Metastasis / pathology. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery
  • [MeSH-minor] Adult. Biopsy. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Hysterectomy. Laparotomy. Recurrence

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19406461.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


55. Gombos Z, Xu X, Chu CS, Zhang PJ, Acs G: Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix. Clin Cancer Res; 2005 Dec 1;11(23):8364-71
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Lymphatic invasion and nodal metastasis plays a major role in the spread of cervical cancer; however, little is known about the mechanisms whereby tumor cells enter the lymphatic system.
  • EXPERIMENTAL DESIGN: We examined the intra- and peritumoral lymphatic vessel density (LVD) using D2-40 immunohistochemistry in 111 cervical squamous cell carcinomas and correlated them with vascular endothelial growth factor (VEGF)-C expression, clinicopathologic tumor features, and outcome.
  • RESULTS: Compared with benign cervix, intratumoral and peritumoral LVD was significantly increased (P < 0.0001).
  • High peritumoral, but not intratumoral, LVD showed significant correlation with high tumor stage, lymphatic invasion, and nodal metastasis.
  • CONCLUSIONS: Our findings suggest a potential role for VEGF-C in tumor-induced lymphangiogenesis represented by high peritumoral LVD, which may be one of the mechanisms leading to lymphatic invasion and metastatic spread.
  • [MeSH-minor] Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Humans. Lymphangiogenesis. Lymphatic Metastasis. Neoplasm Staging. Neoplasms / metabolism. Neoplasms / pathology. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16322297.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


56. Papantoniou V, Koutsikos J, Sotiropoulou M, Feida E, Tsiouris S: Recurrent bilateral mammary fibromatosis (desmoid tumor) imaged with technetium-99m pentavalent dimercaptosuccinic acid [99mTc-(V)DMSA] scintimammography. Gynecol Oncol; 2005 Jun;97(3):964-9
Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent bilateral mammary fibromatosis (desmoid tumor) imaged with technetium-99m pentavalent dimercaptosuccinic acid [99mTc-(V)DMSA] scintimammography.
  • BACKGROUND: Breast fibromatosis is a rare, benign, recurring, locally destructive entity.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Fibromatosis, Aggressive / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Technetium. Technetium Tc 99m Dimercaptosuccinic Acid
  • [MeSH-minor] Adult. Female. Humans. Mammography / methods

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • Genetic Alliance. consumer health - Fibromatosis.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15896828.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 494JNQ8L28 / Technetium Tc 99m Dimercaptosuccinic Acid; 7440-26-8 / Technetium
  •  go-up   go-down


57. Powless CA, Bakkum-Gamez JN, Aletti GD, Cliby WA: Random peritoneal biopsies have limited value in staging of apparent early stage epithelial ovarian cancer after thorough exploration. Gynecol Oncol; 2009 Oct;115(1):86-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We sought to define the clinical significance of random peritoneal biopsies of otherwise benign appearing tissues in staging of grossly early EOC.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Epithelial Cells / pathology. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult


58. Senay S, Kaya U, Cagil H, Demirkiran F, Alhan C: Surgical management of intravenous leiomyoma with cardiac extension. Do we need total circulatory arrest? Thorac Cardiovasc Surg; 2007 Aug;55(5):322-3
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intravenous leiomyoma of the uterus is a histologically benign, smooth-muscle tumor and may extend through the inferior vena cava into the right atrium.
  • Surgical treatment is mandatory and single-stage resection of the tumor has gained wide acceptance as a safe and easy procedure.
  • [MeSH-major] Angiomyoma / pathology. Angiomyoma / surgery. Heart Arrest, Induced. Neoplasm Recurrence, Local / pathology. Uterine Neoplasms / pathology. Uterus / blood supply. Uterus / pathology. Vena Cava, Inferior / pathology
  • [MeSH-minor] Adult. Cardiac Surgical Procedures. Female. Gynecologic Surgical Procedures. Heart Atria / pathology. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629864.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


59. Farrell R, Scurry J, Otton G, Hacker NF: Clinicopathologic review of malignant polyps in stage 1A carcinoma of the endometrium. Gynecol Oncol; 2005 Aug;98(2):254-62
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of a malignant polyp was determined and a pathological description made of the tumor.
  • Clinical data were collected, including prior tamoxifen usage, tumor recurrence and survival.
  • Three out of the four recurrences occurred in high-grade tumor subtypes and all four had a large primary tumor (size > or = 4 cm).
  • When comparing the same subtype of tumor with and without a malignant polyp, there was no significant difference in clinical outcome.
  • Serous carcinoma commonly arises within an otherwise benign endometrial polyp.
  • Clinical outcome of stage 1A endometrial carcinoma was related to the histological subtype and the size of the tumor rather than the presence of a malignant polyp.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Tamoxifen / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936803.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


60. He Y, Yang KX, Yang F, Wu XL: Primary solitary fibrous tumor of the vulva: a case report. J Reprod Med; 2010 Sep-Oct;55(9-10):452-6
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary solitary fibrous tumor of the vulva: a case report.
  • BACKGROUND: Solitary fibrous tumor (SFT) of the female genital tract is an extremely rare neoplasm of mesenchymal origin.
  • The tumor presented as a 10-cm, well-circumscribed lump and was composed of bland-looking cells admixed with thin and thick collagen fibers with the appearance of hemangiopericytoma.
  • Microscopic evaluation and immunohistochemistry supported the diagnosis of a primary benign vulvar SFT.
  • The outcome of this tumor is based mostly on complete surgical resection.
  • [MeSH-minor] Adult. Female. Gynecologic Surgical Procedures. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21043376.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Simon I, Katsaros D, Rigault de la Longrais I, Massobrio M, Scorilas A, Kim NW, Sarno MJ, Wolfert RL, Diamandis EP: B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol Oncol; 2007 Aug;106(2):334-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: This study characterizes the expression of the novel biomarker B7-H4 in ovarian cancer tissue, normal ovaries, and benign ovarian tumors, and evaluates its relationship to CA125.
  • For comparison, ovarian tissues from patients with benign ovarian tumors (n=43) and patients with normal ovaries (n=32) were tested.
  • CONCLUSION: B7-H4 expression was low in normal ovaries and in benign tumors while half of early stage and two-thirds of late stage cancers over-expressed B7-H4.
  • [MeSH-major] Antigens, CD80 / biosynthesis. Biomarkers, Tumor / biosynthesis. CA-125 Antigen / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Middle Aged. Neoplasm Staging. V-Set Domain-Containing T-Cell Activation Inhibitor 1

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498784.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 0 / VTCN1 protein, human
  •  go-up   go-down


62. Taylor DD, Gercel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol; 2008 Jul;110(1):13-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer.
  • While expression patterns of a recently identified biomarker family, microRNA, appear to be characteristic of tumor type and developmental origin, microRNA profiling has been limited to tissue specimens.
  • Tumors actively release exosomes into the peripheral circulation and we now demonstrate the association of microRNAs with circulating tumor-derived exosomes.
  • METHODS: Circulating tumor exosomes were isolated using a modified MACS procedure with anti-EpCAM.
  • Initially, microRNA profiles of ovarian tumors were compared to those of tumor exosomes isolated from the same patients.
  • Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.
  • RESULTS: MicroRNA from ovarian tumor cells and exosomes from the same patients were positive for 218 of 467 mature microRNAs analyzed.
  • While EpCAM-positive exosomes were detectable in both patients with benign ovarian disease and ovarian cancer, exosomal microRNA from ovarian cancer patients exhibited similar profiles, which were significantly distinct from profiles observed in benign disease.
  • CONCLUSIONS: These results suggest that microRNA profiling of circulating tumor exosomes could potentially be used as surrogate diagnostic markers for biopsy profiling, extending its utility to screening asymptomatic populations.
  • [MeSH-major] Biomarkers, Tumor / blood. MicroRNAs / genetics. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Endocytosis. Female. Gene Expression Profiling. Humans. Lipid Bilayers. Neoplasm Staging. RNA, Neoplasm / blood. RNA, Neoplasm / genetics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2008 Jul;110(1):1-2 [18589207.001]
  • [ErratumIn] Gynecol Oncol. 2010 Jan;116(1):153
  • (PMID = 18589210.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA98166
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lipid Bilayers; 0 / MicroRNAs; 0 / RNA, Neoplasm
  •  go-up   go-down


63. Qu D, Qu H, Fu M, Zhao X, Liu R, Sui L, Zhan Q: Increased expression of Nlp, a potential oncogene in ovarian cancer, and its implication in carcinogenesis. Gynecol Oncol; 2008 Aug;110(2):230-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Nlp expression in normal, borderline, benign and malignant epithelial ovarian tissues was examined by immunohistochemistry.
  • The correlation between Nlp expression and tumor grade, FIGO stage and histological type was also evaluated.
  • RESULTS: Nlp was positive in 1 of 10 (10%) normal ovarian tissues, 5 of 34 (14.7%) benign tumors, 9 of 26 (34.6%) borderline tumors and 73 of 131 (56.0%) ovarian tumors.
  • Nlp immunoreactivity intensity significantly correlated with tumor grade, but not with FIGO stage or histological type.
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Apoptosis / physiology. Cell Growth Processes / physiology. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Paclitaxel / pharmacology. Survival Rate. Transfection

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538832.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Microtubule-Associated Proteins; 0 / NIp protein, human; 0 / Nuclear Proteins; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


64. Klasa-Mazurkiewicz D, Narkiewicz J, Milczek T, Lipińska B, Emerich J: Maspin overexpression correlates with positive response to primary chemotherapy in ovarian cancer patients. Gynecol Oncol; 2009 Apr;113(1):91-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Experimental studies revealed that maspin suppresses tumor growth, angiogenesis, invasion and metastasis.
  • METHODS: Tissue samples consisted of 42 benign tumors, 10 borderline (LMP) tumors, 76 ovarian carcinomas, 8 Krukenberg tumors and 32 normal tissues.
  • RESULTS: Relative maspin level was significantly higher in patients with LMP tumors (median 0.74) and early stages ovarian cancers (median 0.46) when compared with healthy tissues (median 0.03), those with benign (median 0.23) and metastatic tumors (median 0.22).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Female. Humans. Krukenberg Tumor / drug therapy. Krukenberg Tumor / metabolism. Krukenberg Tumor / pathology. Middle Aged. Neoplasm Staging. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19193429.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


65. Galani P, Kapetanakis S, Papadopoulos C, Dimitrakopoulou G, Kosma L, Lafoyianni S, Dimitrakova E, Papathanasiou J, Fiska A: Hypovolemic shock due to giant uterus leiomyoma detachment. Akush Ginekol (Sofiia); 2010;49(5):68-71
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Uterine leiomyoma (UL) is the most common benign gynecologic tumor of the reproductive age females.
  • [MeSH-minor] Female. Humans. Middle Aged. Uterus / pathology. Uterus / surgery

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21265397.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


66. Nam EJ, Yun MJ, Oh YT, Kim JW, Kim JH, Kim S, Jung YW, Kim SW, Kim YT: Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecol Oncol; 2010 Mar;116(3):389-94
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Histopathology showed benign tumors in 25 patients, borderline tumors in 13 patients, and malignant tumors in 95 patients.
  • In distinguishing malignant/borderline from benign ovarian tumors, the accuracy of PET/CT (0.921) was higher than that of pelvis US (0.830) and abdomino-pelvic CT or pelvis MRI (0.749; P=0.013).
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. ROC Curve. Radiopharmaceuticals. Tomography, X-Ray Computed. Ultrasonography, Doppler. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19926121.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


67. Coosemans A, Moerman P, Verbist G, Maes W, Neven P, Vergote I, Van Gool SW, Amant F: Wilms' tumor gene 1 (WT1) in endometrial carcinoma. Gynecol Oncol; 2008 Dec;111(3):502-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms' tumor gene 1 (WT1) in endometrial carcinoma.
  • OBJECTIVE: Wilms' tumor gene (WT1), located on chromosome 11, encodes a transcription factor that contributes to the carcinogenesis of uterine sarcomas.
  • Three slides from different sites of the tumor were analysed.
  • To compare, WT1 expression was also evaluated by IHC in benign endometrium (12) and benign endometrial polyps (5).
  • RESULTS: WT1 positivity was noticed in tumor cells and endothelial cells, lining the intratumoral blood vessels.
  • Comparing the staining patterns of the 3 different bioptic sites, tumor heterogeneity was demonstrated in the majority (72%) of samples.
  • [MeSH-major] Endometrial Neoplasms / genetics. Genes, Wilms Tumor
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Aged. Biopsy. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Female. Humans. Immunohistochemistry. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction. WT1 Proteins / biosynthesis. WT1 Proteins / genetics

  • Genetic Alliance. consumer health - Wilms' tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18929401.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / WT1 Proteins
  •  go-up   go-down


68. Rabban JT, Dal Cin P, Oliva E: HMGA2 rearrangement in a case of vulvar aggressive angiomyxoma. Int J Gynecol Pathol; 2006 Oct;25(4):403-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histogenesis of aggressive angiomyxoma, an uncommon mesenchymal neoplasm of the vulvar, pelvic, and perineal soft tissues, is poorly understood, although the neoplastic cells exhibit a myofibroblastic phenotype.
  • HMGA2 involvement has also been described in a variety of benign gynecologic mesenchymal neoplasms.
  • [MeSH-minor] Adult. Female. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990720.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HMGA2 Protein
  •  go-up   go-down


69. Rim SY, Kim SM, Choi HS: Struma ovarii showing clinical characteristics of ovarian malignancy. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1156-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Struma ovarii is a rare form of ovarian neoplasm, composed entirely or predominantly of thyroid tissue and generally a benign germ cell tumor of the ovary.
  • We experienced a rare case of a postmenopausal woman with benign struma ovarii associated with massive ascites, a complex pelvic mass.
  • No recurrence of the ascites or of the tumor has been observed during the 10-month follow-up.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Ovarian Neoplasms / pathology. Struma Ovarii / pathology. Teratoma / pathology
  • [MeSH-minor] Ascites / etiology. Female. Gynecologic Surgical Procedures. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343201.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


70. Panici PB, Palaia I, Bellati F, Pernice M, Angioli R, Muzii L: Laparoscopy compared with laparoscopically guided minilaparotomy for large adnexal masses: a randomized controlled trial. Obstet Gynecol; 2007 Aug;110(2 Pt 1):241-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: Laparoscopically guided minilaparotomy, when compared with laparoscopy, is able to reduce intraperitoneal spillage in patients with presumably benign large adnexal masses, with minimal increase in patient short- and long-term discomfort.
  • Because data regarding the importance of intraperitoneal spillage during surgery for benign and malignant pathologies, as well as rupture rates during traditional laparotomy, are scarce, traditional laparotomy still represents the standard treatment.
  • [MeSH-major] Adnexal Diseases / surgery. Gynecologic Surgical Procedures / methods. Laparoscopy / methods
  • [MeSH-minor] Adult. Female. Humans. Laparotomy / adverse effects. Laparotomy / methods. Neoplasm Seeding. Ovarian Cysts / pathology. Ovarian Cysts / surgery. Ovarian Neoplasms / surgery. Peritoneal Cavity. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17666596.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


71. Tassi RA, Bignotti E, Rossi E, Falchetti M, Donzelli C, Calza S, Ravaggi A, Bandiera E, Pecorelli S, Santin AD: Overexpression of mammaglobin B in epithelial ovarian carcinomas. Gynecol Oncol; 2007 Jun;105(3):578-85
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Mammaglobin B expression was evaluated by real-time PCR and/or immunohistochemistry in fresh-frozen biopsies and paraffin-embedded tissues derived from a total of 137 patients including 69 primary EOC with different histologies, 28 serous papillary omental metastasis, 8 borderline tumors, 26 benign cystadenomas and 14 normal ovaries.
  • In agreement with real-time PCR results, EOC were found to express significantly higher levels of Mammaglobin B protein when compared to normal ovaries and benign cystadenomas (p<0.01).
  • [MeSH-major] Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / immunology. Uteroglobin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Cell Line, Tumor. Female. Gene Expression. Humans. Immunohistochemistry. Mammaglobin B. Middle Aged. Myelin Proteins. Polymerase Chain Reaction. Proteolipids. Secretoglobins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343903.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin B; 0 / Myelin Proteins; 0 / Neoplasm Proteins; 0 / Proteolipids; 0 / SCGB2A1 protein, human; 0 / Secretoglobins; 9060-09-7 / Uteroglobin
  •  go-up   go-down


72. Zhang J, Li YL, Zhou CY, Hu YT, Chen HZ: Expression of octamer-4 in serous and mucinous ovarian carcinoma. J Clin Pathol; 2010 Oct;63(10):879-83
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Oct4 expression was significantly increased from normal epithelium (both ovarian epithelium and fallopian tube epithelium) to benign and borderline cystadenoma to carcinoma in the serous lesion subgroup.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cystadenoma / metabolism. Octamer Transcription Factor-3 / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Disease Progression. Epithelium / metabolism. Fallopian Tubes / metabolism. Female. Humans. Neoplasm Proteins / metabolism. Neoplasm Staging. Ovary / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876318.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human
  •  go-up   go-down


73. Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Gao F, Herzog TJ: Relationship of ovarian neoplasms and body mass index. J Reprod Med; 2005 Aug;50(8):595-602
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe the distribution of benign and malignant ovarian neoplasms among overweight and obese women.
  • Benign ovarian neoplasms occurred in 20-25% of the women.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Body Weight / physiology. Child. Cohort Studies. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Ovarian Cysts / diagnosis. Ovarian Cysts / pathology. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16220765.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Hein S, Mahner S, Kanowski C, Löning T, Jänicke F, Milde-Langosch K: Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines. Oncol Rep; 2009 Jul;22(1):177-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of pc-Jun, Jun B, Jun D and Fra-2 was higher in invasive cancer compared to benign tumors.
  • These results suggest that AP-1 proteins are differentially expressed in benign ovarian tumors, tumors with low malignant potential and epithelial ovarian carcinomas and metastases.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Cell Movement. Cell Proliferation. Female. Fos-Related Antigen-2 / metabolism. Humans. Middle Aged. Neoplasm Invasiveness. Time Factors


75. Magtibay PM, Salmon Z, Keeney GL, Podratz KC: Aggressive angiomyxoma of the female pelvis and perineum: a case series. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):396-401
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive angiomyxoma of the female pelvis and perineum: a case series.
  • These tumors are benign, locally infiltrative mesenchymal neoplasms with a predilection for the female pelvis and perineum and a tendency to recur.
  • Surgical excision remains the mainstay of treatment, but whether clear, tumor-free surgical margins are necessary is controversial.
  • [MeSH-major] Biomarkers, Tumor / analysis. Myxoma / pathology. Pelvic Neoplasms / pathology. Perineum / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Female. Gynecologic Surgical Procedures / methods. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Risk Assessment. Sampling Studies. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445665.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


76. Youm HS, Cha DS, Han KH, Park EY, Hyon NN, Chong Y: A case of huge sclerosing stromal tumor of the ovary weighing 10 kg in a 71-year-old postmenopausal woman. J Gynecol Oncol; 2008 Dec;19(4):270-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of huge sclerosing stromal tumor of the ovary weighing 10 kg in a 71-year-old postmenopausal woman.
  • Sclerosing stromal tumor (SST) is a rare benign neoplasm of ovarian stromal origin and predominantly affects young women in the second and third decades.
  • This tumor characteristically differentiates itself histologically and clinically from both thecomas and fibromas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2003 Oct;443(4):549-60 [12910419.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):318-9 [11330969.001]
  • [Cites] Obstet Gynecol. 1975 Jun;45(6):675-9 [1143729.001]
  • [Cites] Adv Anat Pathol. 2007 Sep;14(5):305-19 [17717430.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):207-15 [15972425.001]
  • [Cites] Ultrasound Obstet Gynecol. 2003 Nov;22(5):531-4 [14618669.001]
  • [Cites] Gynecol Oncol. 1976 Sep;4(3):335-9 [964703.001]
  • [Cites] Cancer. 1973 Mar;31(3):664-70 [4348335.001]
  • [Cites] Clin Radiol. 2000 Dec;55(12):899-911 [11124069.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Dec;83(3):319-21 [14643050.001]
  • [Cites] Histopathology. 1979 Sep;3(5):367-76 [488921.001]
  • (PMID = 19471655.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676485
  • [Keywords] NOTNLM ; Ovary / Sclerosing stromal tumor
  •  go-up   go-down


77. Spannuth WA, Rocconi RP, Kirby TO, Huh WK, Conner MG: Gamma mode of infiltration associated with poor prognosis in malignant teratoma of the ovary: A case report. Gynecol Oncol; 2005 Jul;98(1):155-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although mature cystic teratoma is the most common tumor of the ovary, squamous cell carcinoma arising from a mature teratoma is a rare event.
  • Prognosis depends on clinical stage, grade, and recently described mode of tumor infiltration.
  • Final pathology demonstrated poorly differentiated squamous cell carcinoma with gamma mode of tumor infiltration.
  • CONCLUSION: Squamous cell carcinoma arising from a benign cystic teratoma is a rare event.
  • This case supports the growing evidence linking the mode of tumor infiltration with overall prognosis of survival.
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15922442.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Ahn HJ, Bae J, Lee S, Ko JE, Yoon S, Kim SJ, Sakuragi N: Differential expression of clusterin according to histological type of endometrial carcinoma. Gynecol Oncol; 2008 Aug;110(2):222-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mRNA and protein expressions of clusterin in endometrioid carcinoma were higher than in benign endometrium (p=0.002).
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Estradiol / pharmacology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Paraffin Embedding. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Stimulation, Chemical

  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18514801.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLU protein, human; 0 / Clusterin; 0 / RNA, Messenger; 4TI98Z838E / Estradiol
  •  go-up   go-down


79. Kurman RJ, Shih IeM: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol; 2010 Mar;34(3):433-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian cancer is the most lethal gynecologic malignancy.
  • Moreover, the carcinomas exhibit a shared lineage with the corresponding benign cystic neoplasm, often through an intermediate (borderline tumor) step, supporting the morphologic continuum of tumor progression.
  • Thus, it has been proposed that serous tumors arise from the implantation of epithelium (benign or malignant) from the fallopian tube.


80. Walsh C, Holschneider C, Hoang Y, Tieu K, Karlan B, Cass I: Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol; 2005 Oct;106(4):693-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the 26 cases of coexisting ovarian involvement, 12 (46%) had grade 1 endometrial cancer on preoperative biopsy, 4 (15%) had normal preoperative imaging of the adnexa, and 4 (15%) had benign-appearing ovaries at the time of intraoperative assessment.
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Ovariectomy. Retrospective Studies. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Obstet Gynecol. 2005 Oct;106(4):680-1 [16199620.001]
  • (PMID = 16199623.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Sakurai H, Suzuki Y, Nonaka T, Ishikawa H, Shioya M, Kiyohara H, Katoh H, Nakayama Y, Hasegawa M, Nakano T: FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy--tumor volume and FDG uptake value. Gynecol Oncol; 2006 Mar;100(3):601-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy--tumor volume and FDG uptake value.
  • Rationale for FDG-PET was the presence of symptoms in 6 patients, abnormal serum tumor marker values in 13, abnormal lesions on other diagnostic imaging modalities in 19, and patient request in 2.
  • Maximum tumor diameter and tumor volume in the corresponding disease were estimated by computed tomography (CT) or magnetic resonance imaging (MRI).
  • Three false-positive cases were a localized pneumonitis, a benign pubic bone fracture, and a fibrosis after interstitial brachytherapy.
  • Regarding tumor volume measurement, good correlation between maxSUV on FDG-PET and tumor volume was obtained (lung metastases, P = 0.03; extrapelvic nodes, P < 0.0001).
  • This study suggests that FDG uptake is associated with tumor volume, and FDG-PET has limitations in the detection of lesions less than 1 cm3 or microscopic disease.
  • Careful diagnostic agreement between PET and CT/MRI for positive but benign lesions, such as inflammation and bone fracture, remains important.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Uterine Cervical Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16257440.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


82. Ødegaard E, Staff AC, Kaern J, Flørenes VA, Kopolovic J, Tropé CG, Abeler VM, Reich R, Davidson B: The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma. Gynecol Oncol; 2006 Mar;100(3):462-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: AP-2gamma was detected in the nucleus of tumor cells in 28/75 (37%) borderline tumors, 13/22 (59%) FIGO stage I carcinomas, and 255/306 (83%) advanced-stage carcinomas (P < 0.001, Chi-square test).
  • Benign ovaries were uniformly negative.
  • CONCLUSIONS: AP-2gamma expression is upregulated in advanced-stage ovarian carcinoma compared to early-stage carcinomas, borderline tumors, and the ovarian surface epithelium, and AP-2gamma is specifically localized to cancer cells in effusions, suggesting a role in tumor progression.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Nucleus / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Proto-Oncogene Proteins c-kit / metabolism. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16216317.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transcription Factor AP-2; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


83. Brustmann H: Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study. Gynecol Oncol; 2005 Sep;98(3):396-402
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Formalin-fixed, paraffin-embedded archival tissue sections of 10 benign serous cystadenomas, 10 serous neoplasms of low malignant potential (LMP), and 41 serous ovarian carcinomas were immunostained with antibodies to hTERT and c-kit.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Cystadenocarcinoma, Serous / enzymology. DNA-Binding Proteins / biosynthesis. Ovarian Neoplasms / enzymology. Proto-Oncogene Proteins c-kit / biosynthesis. Telomerase / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Growth Processes / physiology. Female. Humans. Immunohistochemistry. Middle Aged. Mitosis / physiology. Neoplasm Staging. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16005054.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


84. Chen MY, Ng KK, Ma SY, Wu TI, Chang TC, Lai CH: False-positive fluorine-18 fluorodeoxy-D-glucose positron emission tomography imaging caused by retained gauze in a woman with recurrent ovarian cancer: a case report. Eur J Gynaecol Oncol; 2005;26(4):451-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During surgical intervention, the left supraheptic tumor was excised and the gauze with surrounding granulation was removed.
  • This case demonstrates that PET results should be interpreted with caution in differentiating a benign inflammatory process from malignant abnormalities, especially in regions with a high probability of granulomatous lesions.
  • [MeSH-major] Adenocarcinoma, Papillary / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Ovarian Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Surgical Sponges
  • [MeSH-minor] False Positive Reactions. Female. Fluorodeoxyglucose F18. Foreign-Body Reaction / radionuclide imaging. Foreign-Body Reaction / surgery. Humans. Middle Aged. Radiopharmaceuticals. Surgical Procedures, Operative

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16122202.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


85. Gaarenstroom KN, van der Hiel B, Tollenaar RA, Vink GR, Jansen FW, van Asperen CJ, Kenter GG: Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:54-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No peritoneal carcinoma was found among those 114 women who underwent bilateral salpingo-oophorectomy with normal or benign pathology results, after a mean follow-up of 16 months (152 person-years).
  • [MeSH-minor] Adult. Aged. CA-125 Antigen / blood. Cohort Studies. Female. Follow-Up Studies. Genes, BRCA1. Genes, BRCA2. Genetic Predisposition to Disease. Gynecologic Surgical Procedures. Humans. Mass Screening. Middle Aged. Neoplasm Staging. Treatment Outcome


86. Wang E, Ngalame Y, Panelli MC, Nguyen-Jackson H, Deavers M, Mueller P, Hu W, Savary CA, Kobayashi R, Freedman RS, Marincola FM: Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res; 2005 Jan 1;11(1):113-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To study the role of the peritoneum in fostering tumor invasion, we analyzed differences between the transcriptional repertoires of peritoneal tissue lacking detectable cancer in patients with EOC versus benign gynecologic disease.
  • EXPERIMENTAL DESIGN: Specimens were collected at laparotomy from patients with benign disease (b) or malignant (m) ovarian pathology and comprised primary ovarian tumors, paired bilateral specimens from adjacent peritoneum and attached stroma (PE), subjacent stroma (ST), peritoneal washes, ascites, and peripheral blood mononuclear cells.
  • RESULTS: Principal component analysis and unsupervised clustering did not segregate specimens from patients with benign or malignant pathology.
  • Class comparison identified differences between benign and malignant PE and ST specimens deemed significant by permutation test (P = 0.027 and 0.012, respectively).
  • [MeSH-minor] Computational Biology. DNA, Complementary / metabolism. Extracellular Matrix / metabolism. Female. Humans. Neoplasm Invasiveness. Neoplasm Metastasis. Oligonucleotide Array Sequence Analysis. Ovary / pathology. Peritoneum / pathology. RNA / metabolism. Transcription, Genetic. Up-Regulation

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671535.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 63231-63-0 / RNA
  •  go-up   go-down


87. Zhang H, Kong B, Qu X, Jia L, Deng B, Yang Q: Biomarker discovery for ovarian cancer using SELDI-TOF-MS. Gynecol Oncol; 2006 Jul;102(1):61-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To discover the possible diagnostic biomarker for ovarian cancer, a preliminary training set of spectra derived from 31 primary ovarian cancer patients, 16 patients with benign ovarian diseases, and 25 healthy women was used to develop a proteomic model that discriminated cancer from non-cancer effectively.
  • [MeSH-major] Biomarkers, Tumor / blood. Blood Proteins / analysis. Ovarian Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Staging. Proteomics / methods. Reproducibility of Results. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16403569.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins
  •  go-up   go-down


88. Bellone S, Watts K, Cane' S, Palmieri M, Cannon MJ, Burnett A, Roman JJ, Pecorelli S, Santin AD: High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol Oncol; 2005 Jul;98(1):92-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate and compare autocrine expression and production of interleukin-6 (IL-6), a pleiotropic cytokine involved in the resistance to cytotoxic agents and inhibition of anti-tumor immune function in endometrial carcinoma in vitro as well as in vivo.
  • Secretion of IL-6 protein by 6 primary endometrial tumor cultures including USPC and EC was measured using a sensitive enzyme-linked immunosorbent assay (ELISA) in vitro.
  • Finally, IL-6 concentration in 71 serum samples including 20 apparently healthy women, 19 women with benign abdominal diseases, 19 women with primary EC, and 13 USPC patients was studied.
  • IL-6 serum concentrations between normal healthy females (range 0.01-21.23 pg/ml; mean 3.1 pg/ml) and benign disease patients (range 0.01-95.77 pg/ml; mean 13.07 pg/ml) were not statistically different.
  • [MeSH-minor] Adult. Drug Resistance, Neoplasm. Female. Humans. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15904949.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6
  •  go-up   go-down


89. Cole LA, Muller CY: Hyperglycosylated hCG in the management of quiescent and chemorefractory gestational trophoblastic diseases. Gynecol Oncol; 2010 Jan;116(1):3-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These are quiescent gestational trophoblastic disease, defined as inactive or benign invasive disease, and minimally invasive gestational trophoblastic disease, defined as slow growing or chemorefractory disease with hCG increasing very slowly (doubling rate 2-6 weeks).
  • [MeSH-minor] Adult. Drug Resistance, Neoplasm. Female. Glycosylation. Humans. Middle Aged. Pregnancy. Reference Values. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2010 Jun;117(3):505 [20144843.001]
  • [CommentIn] Gynecol Oncol. 2010 Jun;117(3):505-6; author reply 506-7 [20181383.001]
  • (PMID = 19822356.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  •  go-up   go-down


90. Davidson B, Elstrand MB, McMaster MT, Berner A, Kurman RJ, Risberg B, Trope CG, Shih IeM: HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol; 2005 Jan;96(1):42-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma.
  • OBJECTIVE: We recently showed that the levels of secreted human leukocyte antigen-G (HLA-G), a nonclassical MHC class I antigen, are significantly elevated in malignant effusions in ovarian carcinoma compared to benign ones.
  • HLA-G expression in tumor cells was significantly lower in effusions obtained during or following chemotherapy (P = 0.038).
  • The presence of HLA-G-positive tumor cells in effusions obtained prior to the institution of chemotherapy correlated with better overall survival (P = 0.042).
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. HLA Antigens / biosynthesis. Histocompatibility Antigens Class I / biosynthesis. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / chemistry. Ascitic Fluid / immunology. Female. HLA-G Antigens. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Pleural Effusion / immunology. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589578.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


91. Koensgen D, Mustea A, Klaman I, Sun P, Zafrakas M, Lichtenegger W, Denkert C, Dahl E, Sehouli J: Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression. Gynecol Oncol; 2007 Nov;107(2):266-73
SciCrunch. HGNC: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
  • OBJECTIVE: The plasminogen activator system (PA) plays an important role in invasion and metastasis of solid tumors.
  • A thorough expression analysis of PAI-RBP1 and PAI-1 was performed in normal ovary (n=4), benign (n=6) and malignant (n=42) ovarian lesions using non-radioactive RNA in situ hybridization and immunohistochemistry, respectively.
  • RESULTS: PAI-RBP1 mRNA and PAI-1 were significantly overexpressed in tumor epithelial cells as compared to benign and normal ovarian tissue.
  • CONCLUSION: In ovarian cancer, PAI-RBP1 is significantly overexpressed in tumor epithelial cells, suggesting a biological role in tumor invasion and metastasis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / chemistry. Carcinoma / pathology. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / pathology. Plasminogen Activator Inhibitor 1 / analysis. Retinol-Binding Proteins, Cellular / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Neoplasm, Residual. Predictive Value of Tests. Prognosis. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Survival Analysis. Up-Regulation


92. Bipat S, Fransen GA, Spijkerboer AM, van der Velden J, Bossuyt PM, Zwinderman AH, Stoker J: Is there a role for magnetic resonance imaging in the evaluation of inguinal lymph node metastases in patients with vulva carcinoma? Gynecol Oncol; 2006 Dec;103(3):1001-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on these characteristics, each lymph node was classified as malignant or benign and subsequently each groin was classified as malignant or benign.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Groin / pathology. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Observer Variation. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16859737.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Whittaker CS, Coady A, Culver L, Rustin G, Padwick M, Padhani AR: Diffusion-weighted MR imaging of female pelvic tumors: a pictorial review. Radiographics; 2009 May-Jun;29(3):759-74; discussion 774-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted MR imaging of female pelvic tumors: a pictorial review.
  • Diffusion-weighted MR imaging studies of female pelvic tumors have shown reduced apparent diffusion coefficient (ADC) values within cervical and endometrial tumors.
  • In addition, this unique noninvasive modality has demonstrated the capacity to help discriminate between benign and malignant uterine lesions and to help assess the extent of peritoneal spread from gynecologic malignancies.
  • Increasing familiarity with ADC calculation and manipulation software will allow radiologists to provide new information for the care of patients with known or suspected gynecologic malignancies.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging. Genital Neoplasms, Female / pathology. Pelvic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Endometrial Neoplasms / pathology. Female. Humans. Leiomyoma / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448114.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


94. Huddleston HG, Wong KK, Welch WR, Berkowitz RS, Mok SC: Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol; 2005 Jan;96(1):77-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE:. (1) To identify and (2) validate genes that are up-regulated in ovarian cancer, and (3) to investigate whether the activity of a candidate gene, creatine kinase B (CKB) is elevated in pre-operative sera from ovarian cancer patients compared to patients with benign pelvic masses and normal controls.
  • METHODS: MICROMAX cDNA microarray system and RNA derived from pooled ovarian cancer cell lines and normal ovary surface epithelial cells (HOSE) were used to identify differentially expressed genes.
  • Using a commercially available enzyme assay, CKB activity was measured in pre-operative serum samples obtained from 45 ovarian cancer patients, 49 patients with a benign pelvic mass, as well as 37 normal controls.
  • In serum, the mean (+/-standard error) of CKB enzyme activity in cancer cases was 24.7 U/L units (+/- 5.1) compared to 9.6 U/L (+/- 1.6) for benign mass cases (P = 0.0088) and to 8.5 U/L (1.7) for normal controls (P = 0.0096).
  • CONCLUSIONS: Microarray technology offers a method to identify tumor biomarkers with potential clinical usefulness.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Creatine Kinase / biosynthesis. Isoenzymes / biosynthesis. Oligonucleotide Array Sequence Analysis / methods. Ovarian Neoplasms / enzymology
  • [MeSH-minor] Adult. Creatine Kinase, BB Form. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589584.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA86381; United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / RNA, Neoplasm; EC 2.7.3.2 / Creatine Kinase; EC 2.7.3.2 / Creatine Kinase, BB Form
  •  go-up   go-down


95. Silvagno F, Poma CB, Realmuto C, Ravarino N, Ramella A, Santoro N, D'Amelio P, Fuso L, Pescarmona G, Zola P: Analysis of vitamin D receptor expression and clinical correlations in patients with ovarian cancer. Gynecol Oncol; 2010 Oct;119(1):121-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We analyzed VDR content in platelets of healthy women and of a cohort of patients with ovarian tumors and we evaluated possible correlations with clinical parameters, tumor characterization (stage, histology, nuclear grading, ascites), response to therapy and survival.
  • In the latter a significant increase in receptor expression was observed in malignancies compared with benign cases.
  • [MeSH-minor] Adult. Aged. Blood Platelets / metabolism. CA-125 Antigen / blood. Cohort Studies. Female. Hemoglobins / metabolism. Humans. Immunohistochemistry. Membrane Proteins / blood. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20599260.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Hemoglobins; 0 / MUC16 protein, human; 0 / Membrane Proteins; 0 / Receptors, Calcitriol
  •  go-up   go-down


96. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancuso S, Scambia G: Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer; 2008 May-Jun;18(3):506-14
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stem cells isolated from nervous system and prostate express CD133 antigen, which is widely used to isolate hematopoietic stem and progenitor cells.
  • Tissue specimens were obtained at primary surgery from 41 ovarian carcinomas; eight normal ovaries and five benign ovarian tumors were also collected.
  • The percentages of CD133-1- and CD133-2-expressing cells were significantly lower in normal ovaries/benign tumors with respect to those in ovarian carcinoma.
  • CD133-1 and CD133-2 may be useful in order to select and enrich the population of CD133(+) ovarian tumor cells, which are characterized by a higher clonogenic efficiency and proliferative potential.
  • [MeSH-major] Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Glycoproteins / metabolism. Neoplasm Invasiveness / pathology. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Peptides / metabolism
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Flow Cytometry. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Probability. Prognosis. Reference Values. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868344.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


97. Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J, Shroyer KR: B7-H4 overexpression in ovarian tumors. Gynecol Oncol; 2006 Jan;100(1):44-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was designed to evaluate the expression of B7-H4 protein, recently identified as a potential molecular marker of breast and ovarian cancer by quantitative PCR analysis, in benign tumors, tumors of low malignant potential and malignant tumors of the ovary.
  • [MeSH-major] Antigens, CD80 / biosynthesis. Biomarkers, Tumor / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / immunology. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / immunology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Blotting, Western. Carcinoma, Endometrioid / immunology. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / immunology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. V-Set Domain-Containing T-Cell Activation Inhibitor 1

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16256178.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Biomarkers, Tumor; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 0 / VTCN1 protein, human
  •  go-up   go-down


98. Rauvala M, Puistola U, Turpeenniemi-Hujanen T: Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol; 2005 Dec;99(3):656-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We measured, prior to primary surgery, the concentrations of these proteins in serum samples of 115 patients with an ovarian tumor: 63 with cancer, 6 with a low malignant potential tumor, and 46 with a benign tumor.
  • RESULTS: A high serum concentration of TIMP-1 at diagnosis was found to correlate with the malignant phenotype of an ovarian tumor.
  • An association was found between a high serum level of TIMP-1 and an advanced stage of the disease, a residual tumor>2 cm, poor response to cytotoxic treatment, shorter recurrence free time, and shorter cancer-related overall survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112717.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tissue Inhibitor of Metalloproteinase-1; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


99. Kikkawa F, Nawa A, Kajiyama H, Shibata K, Ino K, Nomura S: Clinical characteristics and prognosis of mucinous tumors of the ovary. Gynecol Oncol; 2006 Oct;103(1):171-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Ovarian mucinous tumors consist of benign, borderline, and carcinomatous tumor, but the clinical characteristics of these 3 types have not been investigated in detail.
  • METHODS: One hundred sixty-one patients with mucinous cystadenocarcinoma and 143 patients with mucinous borderline tumor were registered between 1986 and 2003.
  • RESULTS: Mean patient ages were 43.9, 44.7, and 49.7 years in patients with benign, borderline, carcinomatous tumor, respectively.
  • The ratio of early stage (I, II) to advanced stage (III, IV) was significantly lower in carcinoma than in borderline tumor.
  • The levels of tumor markers tended to increase with the level of malignancy.
  • In borderline tumor, 5 patients died of disease, and all of these patients had stage III disease with residual tumor after the initial surgery.
  • Patients with borderline tumor showed significantly better prognosis than those with carcinoma; however, there were no significant differences in prognosis between borderline tumor and carcinoma in patients with stage III tumor or residual tumor.
  • CONCLUSIONS: In mucinous tumors, measurement of CA72-4 is recommended to distinguish malignant from benign tumors.
  • Even in borderline tumor, patients with residual tumor showed a poorer prognosis than carcinoma, suggesting that complete resection is necessary for a good prognosis.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carboplatin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546243.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


100. Ni Bhriain H, Trovik J, Wik E, Stefansson IM, Akslen LA, Salvesen HB, Staff AC: Plasma calprotectin concentrations in women with endometrial carcinoma. Gynecol Oncol; 2009 Sep;114(3):491-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also, median calprotectin concentration was elevated in the endometrial cancer group as compared to women with invasive ovarian cancer, borderline ovarian tumor and benign ovarian tumors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. ROC Curve. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577278.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Leukocyte L1 Antigen Complex
  •  go-up   go-down






Advertisement